Journal of Neurology (2021) 268:1133-1170
https://doi.org/10.1007/s00415-020-10124-x
REVIEW 4.)
Check for
updates
Guillain-Barré syndrome spectrum associated with COVID-19:
an up-to-date systematic review of 73 cases
Samir Abu-Rumeileh' - Ahmed Abdelhak'? - Matteo Foschi’ - Hayrettin Tumani’” - Markus Otto'®
Received: 14 June 2020 / Revised: 22 July 2020 / Accepted: 27 July 2020/ Published online: 25 August 2020
© The Author(s) 2020
Abstract
Since coronavirus disease-2019 (COVID-19) outbreak in January 2020, several pieces of evidence suggested an association
between the spectrum of Guillain-Barré syndrome (GBS) and severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2). Most findings were reported in the form of case reports or case series, whereas a comprehensive overview is still
lacking. We conducted a systematic review and searched for all published cases until July 20th 2020. We included 73 patients
reported in 52 publications. A broad age range was affected (mean 55, min 11—max 94 years) with male predominance
(68.5%). Most patients showed respiratory and/or systemic symptoms, and developed GBS manifestations after COVID-19.
However, asymptomatic cases for COVID-19 were also described. The distributions of clinical variants and electrophysi-
ological subtypes resemble those of classic GBS, with a higher prevalence of the classic sensorimotor form and the acute
inflammatory demyelinating polyneuropathy, although rare variants like Miller Fisher syndrome were also reported. Cer-
ebrospinal fluid (CSF) albuminocytological dissociation was present in around 71% cases, and CSF SARS-CoV-2 RNA
was absent in all tested cases. More than 70% of patients showed a good prognosis, mostly after treatment with intravenous
immunoglobulin. Patients with less favorable outcome were associated with a significantly older age in accordance with
previous findings regarding both classic GBS and COVID-19. COVID-19-associated GBS seems to share most features of
classic post-infectious GBS and possibly the same immune-mediated pathogenetic mechanisms. Nevertheless, more extensive
epidemiological studies are needed to clarify these issues.
Keywords COVID-19 - SARS-CoV-2 - Coronavirus - Guillain-Barré syndrome - Miller Fisher syndrome - Neurology -
Autoimmune - Polyradiculopathy - Neuroimmunology
Introduction
Coronavirus disease 2019 (COVID-19) pandemic has rap-
idly spread around the world from Jan-2020, with more than
14,000,000 cases confirmed so far [1]. Although primary
><] Markus Otto
markus.otto
@ uni-ulm.de
Department of Neurology, Ulm University Hospital,
89070 Ulm, Germany
Department of Neurology and Stroke, University Hospital
of Tubingen, 72076 Tiibingen, Germany
Hertie Institute of Clinical Brain Research, University
of Tubingen, 72076 Tiibingen, Germany
* Neurology Unit, S. Maria delle Croci Hospital-AUSL
Romagna, ambito di Ravenna, 48121 Ravenna, Italy
Specialty Hospital of Neurology Dietenbronn,
88477 Schwendi, Germany
affecting the respiratory system, central and peripheral neu-
rological manifestations associated with severe acute respir-
atory syndrome coronavirus 2 (SARS-CoV-2) infection have
been increasingly reported [2-4]. In detail, several pieces of
evidence suggested an association between SARS-CoV-2
infection and the development of Guillain-Barré Syndrome
(GBS) [5-56].
GBS represents the most common cause of acute flac-
cid paralysis [57]. The classic form is an immune-mediated
acute-onset demyelinating polyradiculoneuropathy (acute
inflammatory demyelinating polyneuropathy—AIDP) typi-
cally presenting with ascending weakness, loss of deep ten-
don reflexes, and sensory deficits. Diagnosis of GBS relies
on the results of clinical, electrophysiological, and cerebro-
spinal fluid (CSF) examinations (classically albuminocyto-
logical dissociation) [57-59]. The clinical spectrum of GBS
encompasses a classic sensorimotor form, Miller Fisher syn-
drome (MFS), bilateral facial palsy with paraesthesia, pure
g\ Springer

1134
Journal of Neurology (2021) 268:1133-1170
motor, pure sensory, paraparetic, pharyngeal—cervical—bra-
chial variants, polyneuritis cranialis (GBS—MEFS overlap),
and Bickerstaff brainstem encephalitis [57-60]. As regard
electrophysiological features, three main subtypes are rec-
ognized: AIDP, acute motor axonal neuropathy (AMAN),
and acute motor sensory axonal neuropathy (AMSAN) [57,
58, 61]. Peripheral nerve damage is thought to be provoked
by an aberrant immune response to infections, in some
cases driven by the production of autoreactive antibodies
(anti-ganglioside antibodies) [57-59]. Potential trigger-
ing pathogens include both viruses [e.g., cytomegalovirus
(CMV), Epstein-Barr virus (EBV), influenza virus, hepatitis
E virus, and Zika virus] and bacteria (e.g., Campylobacter
Jejuni, Mycoplasma Pneumoniae) [57, 58, 62]. However, a
relationship with other events has been also described (e.g.,
vaccinations, surgery, administration of checkpoint inhibi-
tors, and malignancy) [57, 58]. Given that a potential causal
association with beta-coronaviruses [Middle East Respira-
tory Syndrome (MERS-CoV)] has already been speculated,
the relationship between COVID-19 and GBS deserves
undoubtedly further attention [63, 64].
With this background, our systematic review aimed to
provide a comprehensive and updated overview of all case
reports and series of COVID-19-related GBS to identify pre-
dominant clinical, laboratory, and neurophysiological pat-
terns and to discuss the possible underlying pathophysiology.
Methods
We performed a systematic review according to the SALSA
(Search, Appraisal, Synthesis, and Analysis) analytic frame-
work [65]. We screened in PubMed and Google Scholar
databases for all case descriptions of GBS associated with
COVID-19 that were published from January 1st 2020 up
to July 20th 2020. Keywords (including all commonly used
abbreviations of these terms) used in the search strategy
were as follows: [acute autoimmune neuropathy” OR “acute
inflammatory demyelinating polyneuropathy” OR “acute
inflammatory demyelinating polyradiculoneuropathy,” OR
“acute inflammatory polyneuropathy” OR “Demyelinating
Polyradiculoneuropathy” OR “Guillain-Barre Syndrome”
OR “Guillain-Barre” OR ““Miller—Fisher” OR “Bickerstaff
encephalitis” OR “AIDP” OR “AMAN” OR “AMSAN” OR
polyneuritis cranialis] AND [“COVID-19” OR “Wuhan
coronavirus” OR “novel coronavirus” OR “novel corona-
virus 2019” OR “SARS” OR “SARS-CoV-2”]. Suitable
references were also identified in the authors’ archives of
scientific literature on GBS. We restricted our search to stud-
ies published in English, Spanish, or Italian. Publications
that were not peer-reviewed were excluded from this study.
PRISMA criteria were applied. For each case, we extracted
data concerning demographic and clinical variables, results
g\ Springer
of diagnostic investigations, and outcome. If the GBS clini-
cal variant [57] or the electrophysiological subtype [61]
was not explicitly reported in the paper, we reconstructed it,
when possible, from reported details. We also classified the
diagnostic certainty of all cases according to the Brighton
Criteria [66]. Searches were performed by SAR, AA, and
MF. The selection of relevant articles was shared with all
authors.
For statistical analysis, we used IBM SPSS Statistics ver-
sion 21 (TBM, Armonk, NY, USA). Based on the distribu-
tion of values, continuous data were expressed as mean +
standard deviation or as median and interquartile range
(IQR). Depending on the number of groups and data distri-
bution, we applied the t test, the Mann-Whitney U test or
the Kruskal-Wallis test (followed by Dunn—Bonferroni post
hoc test). All reported p values were adjusted for multiple
comparisons. We adopted the Chi-square test for categorical
variables. Differences were considered statistically signifi-
cant atp < 0.05.
For the present study, no authorization to an Ethics Com-
mittee was asked, because the original reports, nor this work,
provided any personal information of the patients.
Results
Our literature search identified 101 papers, including 37
case reports, 12 case series, 3 reviews with case reports,
42 reviews, 4 letters, 1 original article, 1 point of view, and
1 brief report. Four and one patients were excluded from
the analysis because of a missing laboratory-proven SARS-
CoV-2 infection or an ambiguous GBS diagnosis [disease
course resembling chronic inflammatory demyelinating neu-
ropathy (CIDP)], respectively. A total of 52 studies were
included in the final analysis (total patients = 73) [S—S6].
All data concerning the analyzed patients are reported in
Table 1. For one case [20], most clinical and diagnostic
details were not reported; therefore, many of our analyses
were limited to 72 patients.
Epidemiological distribution and demographic
characteristics of the patients
To date, GBS cases (1 =73) were reported from all conti-
nents except Australia. In details, patients were originally
from Italy (n=20), Iran (n= 10), Spain (n=9), USA (n=8),
United Kingdom (n=5), France (n=4), Switzerland (n= 4),
Germany (n=3), Austria (n=1), Brazil (n= 1), Canada
(n=1), China (n= 1), India (n= 1), Morocco (n= 1), Saudi
Arabia (n= 1), Sudan (n= 1), The Netherlands (n= 1), and
Turkey (n= 1) (Table 1, Fig. 1). The mean age at onset was
55+17 years (min 11—max 94), including four pediatric
cases [21, 27, 35, 41]. A significative prevalence of men

Journal of Neurology (2021) 268:1133-1170
1135
compared to women was noticed (50 vs. 23 cases: 68.5%
vs. 31.5%) with no significant difference in age at onset
between men and women (mean: 55+ 18 vs. 56+ 16 years,
p=0.643). Comorbidities were variably reported with no
prevalence of a particular disease.
Clinical picture, diagnosis, and therapy of COVID-19
All reported GBS cases (n=72) except two were sympto-
matic for COVID-19 with various severity. Most common
manifestations of COVID-19 included fever (73.6%, 53/72),
cough (72.2%, 52/72), dyspnea and/or pneumonia (63.8%,
46/72), hypo-/ageusia (22.2%, 16/72), hypo-/anosmia
(20.8%, 15/72), and diarrhea (18.1%, 13/72). One of the two
asymptomatic subjects never developed fever, respiratory
symptoms, or pneumonia [10], whereas the other patient
showed an asymptomatic pneumonia at chest computed
tomography (CT) [12]. In all but six patients with available
data [22, 24, 36, 44, 45, 52], SARS-CoV-2 RT-PCR with
naso- or oropharyngeal swab or fecal exam was positive
at first or following tests. Nevertheless, these six patients
tested positive at SARS-CoV-2 serology. In four patients,
the laboratory exam for the diagnostic confirmation was not
specified [20, 40]. Typical “ground glass” aspects at chest-
CT or similar findings at CT, Magnetic Resonance Imag-
ing (MRI) or X-ray compatible with COVID-19 interstitial
pneumonia were reported in 40 cases. The detailed therapies
for COVID-19 are described in Table 1.
Clinical features of GBS spectrum
In all (n=72) but four patients [10, 37, 40, 56], GBS manifes-
tations developed after those of COVID-19 [median (IQR):
14 (7-20), min 2—max 33 days]. Differently, COVID-19
symptoms began concurrent in one case [37], 1 day [40] and
8 days [55] after GBS onset in two other cases and never
developed in another one [10] (Table 1). Common clinical
manifestations at onset included sensory symptoms (72.2%,
52/72) alone or in combination with paraparesis or tetrapa-
resis (65.2%, 47/72, respectively). Cranial nerve involvement
(e.g., facial, oculomotor nerves) was less frequently described
at onset (16.7%, 12/72). Moreover, all cases but one [26]
showed lower limbs or generalized areflexia, whereas in
37.5% (27/72) of the cases, gait ataxia was reported at onset
or during the disease course. Even if ascending weakness
evolving into flaccid tetraparesis (76.4%, 55/72) and spread-
ing/persistence of sensory symptoms (84.7%, 61/72) repre-
sented the most common clinical evolutions, 50.0% (36/72)
and 23.6% (17/72) patients showed cranial nerve deficits and
dysphagia, respectively, during disease course (Table 1).
Moreover, 36.1% (26/72) of the patients developed respira-
tory symptoms, and some of them evolved to respiratory fail-
ure (Table 1). Autonomic disturbances were rarely reported
(16.7%, 12/72). In cases with MFS/MFS-GBS overlap, are-
flexia, oculomotor disturbances, and ataxia were present in
100% (9/9), 66.7% (6/9) and 66.7% (6/9), respectively [8, 19,
23, 30, 32, 33, 43, 44]. The median of time to nadir was cal-
culated in 40 patients with available data and resulted 4 days
(IQR 3-9) (Table 1).
Results of electrophysiological, CSF, biochemical,
and neuroimaging investigations
Detailed electroneurography results were reported in 84.9%
(62/73) of the cases. Specifically, 77.4% (48/62) cases
showed a pattern compatible with a demyelinating polyra-
diculoneuropathy. In contrast, axonal damage was prominent
in 14.5% (9/62). In a minority of the patients (8.1%), a mixed
pattern was reported (5/62). Regarding CSF analysis (full
results were available in 59 out of 73 cases), the classical
albuminocytological dissociation (cell count< 5/ul with
elevated CSF proteins) was detected in 71.2% of the cases
(42/59) with a median CSF protein of 100.0 mg/dl (min: 49,
max: 317 mg/dl). Mild pleocytosis (i.e., cell count> 5/ul),
with a maximum cell count of 13/ul, was evident in 5/59
cases (8.5%). Furthermore, CSF SARS-CoV-2 RNA was
undetectable in all tested patients (1 =31) (Table 1).
Detailed blood haematological and biochemical exami-
nations showed variably leucocytosis (1 =4), leucopenia
(n=17), thrombocytosis (n=3), thrombocytopenia (1 =5),
and increased levels of C-reactive protein (CRP) (n= 22),
erythrocyte sedimentation rate (1 =4), p-Dimer (n=5),
fibrinogen (n= 3), ferritin (1 = 3), LDH (n=7), IL-6 (n=4),
IL-1 (n=3), IL-8 (n=3), and TNF-a (n= 3) (Table 1).
Furthermore, anti-GD1b and anti-GM1 antibodies were
positive in one patient with MEFS [23] and in one with clas-
sic sensorimotor GBS [13], respectively, whereas 33 cases
tested negative (one in equivocal range) for anti-ganglioside
antibodies.
Cranial and spinal MRI scans were performed in a minor-
ity of the patients (23/73, 31.5%). Five patients (three cases
with AIDP [9, 12, 25], one case with MFS [30], and one
case with bilateral facial palsy with paresthesia [52]) showed
cranial nerve contrast enhancement in the context of cor-
respondent cranial nerve palsies. Moreover, brainstem lep-
tomeningeal enhancement was described in two cases with
AIDP, both with clinical cranial nerve involvement [18, 46].
On the other hand, spinal nerve roots and leptomeningeal
enhancement were reported in eight [9, 27, 31, 36, 37, 42,
52] and two cases [17, 46], respectively (Table 1).
Distribution of clinical and electrophysiological
variants and diagnosis of GBS
From the clinical point of view, most examined patients
presented with a classic sensorimotor variant (70.0%,
g\ Springer

1136
Journal of Neurology (2021) 268:1133-1170
51/73), whereas Miller Fisher syndrome, GBS/MFS over-
lap variants (including polyneuritis cranialis), bilateral
facial palsy with paresthesia, pure motor, and paraparetic
were described in seven, two, five, four, and one patients,
respectively. In three cases, no clinical variant could be
established using the reported details (Table 1). In the
examined population, 81.8% subjects fulfilled electro-
physiological criteria for AIDP (45/55), 12.7% (7/55) for
AMSAN, and 5.4% (3/55) for AMAN subtypes. Finally, a
specific electrophysiological subtype was not attributable
in 18 patients due to the lack of detailed information.
The diagnosis of GBS was established based on clinical,
CSF, and electrophysiological findings in 44/73 (60.3%)
patients, clinical, and electrophysiological data in 18/73
(24.7%) cases, clinical, and CSF data in 8/73 (11.0%),
and only clinical findings in 3/73 (4.1%) patients. Indeed,
the highest level of diagnostic certainty (level one) was
confirmed in 44/73 cases (60.3%). Level two and three
were obtained in 24/73 cases (32.9%) and 5/73 (6.8%),
respectively (Table 1).
Management of GBS and patient outcomes
All cases with available therapy data (1 = 70) except ten [13,
15, 23, 25, 26, 33, 35-37, 41] were treated with intrave-
nous immunoglobulin (IVIG) (Table 1). Conversely, plasma
exchange and steroid therapy were performed in ten (four of
them received also [VIG) and two cases, respectively. In two
patients, no therapy was given. Mechanical or non-invasive
ventilation was implemented in 21.4% (15/70) and 7.1%
(5/70) patients due to worsening of GBS or COVID-19,
respectively. At further observation (n=68), 72.1% (49/68)
patients demonstrated clinical improvement with partial or
complete remission, 10.3% (7/68) cases showed no improve-
ment, 11.8% (8/68) still required critical care treatment, and
5.8% (4/68) died (Table 1).
Interestingly, patients with no improvement or poor
outcome (7 = 19) showed a slightly higher (but not signif-
icant) frequency of clinical history and/or a radiological
picture of COVID-19 pneumonia (14/19, 73.7%) com-
pared to those with a favorable prognosis (29/48, 60.4%,
p=0.541). Moreover, the former group of patients was
significantly older (mean 62.7+ 17.8 years, p=0.011),
but with comparable distribution of sex (p =0.622) and
electrophysiological subtypes (p =0.144) and simi-
lar latency between COVID-19 and GBS (p=0.588)
and nadir (p = 0.825), compared to the latter (mean age
51.8+ 16.6 years). The same findings were confirmed
even after excluding cases with no improvement from the
analysis (to prevent a possible bias related to the short
follow-up time).
g\ Springer
Discussion
COVID-19 pandemic prompts all efforts for the early rec-
ognition and treatment of its manifestations. In analogy
to other viruses, belonging or not to the coronavirus fam-
ily [63, 67], neurologic complications in COVID-19 are
emerging as one of the most significant clinical chapters of
this pandemic. In this regard, peripheral and central nerv-
ous system damage in COVID-19 has been postulated to
be the consequence of two different mechanisms: 1) hema-
togenous (infection of endothelial cells or leucocytes) or
trans-neuronal (via olfactory tract or other cranial nerves)
dissemination to central nervous system in relation with viral
neurotropism, and 2) abnormal immune-mediated response
causing secondary neurological involvement [62, 68, 69].
The first mechanism is supposed to be responsible for the
most common neurological symptoms developed by patients
with COVID-19 (e.g., hypogeusia, hyposmia, headache,
vertigo, and dizziness). In contrast, the second can lead to
severe complications during or after the course of the ill-
ness, either dysimmune (e.g., myelitis, encephalitis, GBS) or
induced by cytokine overproduction (hypercoagulable state
and cerebrovascular events) [68, 69].
In the present systematic review, we reviewed clinical
features, results of diagnostic investigations, and outcome
in 73 cases of COVID-19-associated GBS spectrum [5-56].
In the present study, mean age at onset in patients
with GBS largely overlapped that of classic COVID-19 sub-
jects [70, 71]. However, pediatric cases with GBS have been
increasingly reported in the literature [21, 27, 35, 41], sug-
gesting that, with the spreading of the pandemic, a broader
age range might be affected. Moreover, we found a higher
prevalence of GBS in males compared to females, as previ-
ously reported for Zika virus-GBS [72]. This finding may
also reflect the gender epidemiology of SARS-CoV-2. In this
regard, males typically show a worse COVID-19 outcome
compared to the females [70, 71], possibly due to a generally
shorter life expectancy or to higher circulating Angiotensin-
Converting-Enzyme 2 (ACE2) levels, the cellular receptor
for SARS-CoV-2, in the former compared to the latter [71].
Moreover, given that GBS is a rare disease [57] the epide-
miological distribution of the reported cases seems to reflect
current worldwide outbreaks, with Europe being the “hot-
test” spot in March—May 2020 and USA together with Asia
in the following period [73, 74]. On another issue, despite a
few GBS cases seemed to have a para-infectious profile [10,
37, 38, 40, 55, 56] as described for Zika virus [75], all other
reported patients developed neurological symptoms with a
typical latency after COVID-19 (median time 14 days). This
feature, together with the frequently reported negative naso-
pharyngeal swab at GBS onset [22, 24, 36, 44, 45, 52] and
clinical improvement after IVIG therapy, seems to support

1137
1133-1170
Journal of Neurology (2021) 268
yogyjepuon
-BAQTSa]eyed
JOS‘SsoupRaM
SPOSNUNOY
BrxoqorodAy
TIpueTNJoys]“(stsATered
-de[1aA0-noud‘ysnoo(eTuouruotsnjoid‘erseydsAp
JOJOWNIOSASojotsAyd‘eIsnose-nouduoronsuo]‘ssou‘stsojdprpasoJoye
-U9SOISSRIDZ-OF]99[9+[RolVN‘erwsour‘IoaoyWN-dn1oulo9)son.QUON=-YROMJojosseyAlTaaepgsAepOTW6SAfeyy~—s[8]‘Te9Tulssy
BisoyjssodAy
yono}WYsI]pue
pueAVIATISUaS
juopuodap
-Ysusy]
oandasoridoid
vruowneudposearoopTenysr9Ur‘stsoredvied
QIOANSjewrxoid
JOJOW‘eoudsApqosuoplooryaraaosSSOUBOM
OIsseOI+4SO+Teor70dWa‘Ysnoo‘IaaaJ=JoyesAeppONJUON,poziperousry-saisoid4s]sep¢€7W+9oourny[7][e179pneury
voudsApJoouroSuny‘eIxoHorePozipoyeony-[eIoUNs“SqUUTT“wsAInour(UOIs}OU}ULBISOyy
onjor-STLUpeOU]-sovsedpur(erJOJOUpoyeony‘eoudsApyesuo(eTuOw‘stsoredeayjovonny-1LIOSudsSASojotsAydonosya‘UOIS‘(opedsumojdurAs-nouduorploovy‘ssou-OSOIOU)
Issel1+4SO+[eoyyg-ugqiodAYMO[)JOART«JoyesAepp—_-INDUD)soxQUON-yRoMJURpusoOSyeIsoyjsoviedTTJoyesepWILAjay=[9]"Te19HISQTV
ursArnour
onjor
“‘UOIsUayuoOpus}soT[Myoer-roddy‘Ayd‘stsoredeaq-omoddAy==prtutsodAypueplooryoneysoud‘eisnossApSuIpusose
ASojotsAydorosya‘eruoprdiypoqeroosse-soisord‘Asted
JoJOWomg1+JSD+[eorurpa-skqysnooAqVNONVNTerovyTesOIe[IGSSoUyROMTITJaeskep¢W89ATeyy~—s[S]Te30Nsosy
qosuo
Sd)
pue
sumoydurds
ppeN/swodwAssaourqinisipuoomyeqqAqureyi90olowty,ArojerdsayomuouoinyQSINOSBSBISICyOsugOsheq
onsouseipSOpigiowossinjord[eoruryo
qurneaSgHDJO[DAV]sIsouseIpSGDSNOTAI61-GIAOOamjoidjeomipsSGHXOSasVAyyunozspnIy
SOSVdSGDCLUlSUIODINOpuP‘sUONLSSOAUISNSOUSRIpJOS}[Nsar‘ssuIpUy[eotulpSJoAreumuuNns|ajqey
pringer
QS

1133-1170
Journal of Neurology (2021) 268
1138
yorjuoo
vixogompayoadsns
-sovredYIM-soviedyoo}-P]OSTAstederuournoud‘eLmmpresApowoyyeroryA8ootsAydonog[oTenys197UT‘SSOUROMJoye
[eroqe[reI+HSO+[TeomasUON‘onemo\dWAsyVNONouONVN[foes[eroye[laSAvp07W8sepeury=[ZI]TeeueYD
viseydsdp
“eIxoparePIUOUpozifesiouesIoJoul-noud‘ysnooyesuo‘stsoredeo}
-LIOSuasASojorsAydonosya‘(opedsumojdurAsploory‘ssouBisoujsovredJoye[LI]119Issel1+4JSO+[eoQUONYsty)Joaay=JayesAep¢SoxQUON-yeomJUOpUOSYTIpue1sAepLIW+9s0uRdyoyourssopued
uones
-[er9uNs“SUTTeisippue-OoJUur
-MOT[RASpururedsequinanew}IoJoulsuryooodsut‘stsoredeo}-duidse
-LIOSuasASojotsAydAyMoygip‘uonTeisippue0]onp)fot]IsselZ-oogya+TeorONonewojduksyVNONQUON-R[NqWUIeJOSsOT[eUWTxoIdgnoyUMOUyUL)d99Aeyy"Te19BI[seoRIg
euoumoud
TennsiaqurvisoujsovsedayeIOpoUl[esoredpure‘ers[eAUQUITTOIOF
-1IOSUdSASojotsAydonosya“eoUIvIp‘erssumojdurAsSSOT‘SSoUyRom-oredeyayJoye
OIsseOI+4SO+[eoryaAysoqQ-nose‘erusouy=:JayesAep¢SohJUON,Ajoyertdsoy=[eutxoidanoysdepOT4OLoourny=:[6]Te19INesIg
euoumoud
TennsioyurBIXOYOIePOZlPlt‘voyreIp-Teroues‘AstedUMerisnoseSAIOU[BIORJ
anorAqWSL‘erxeye
POMOTLOJ‘sso]UaJosuy,SSOUYBOMJoJOuIUIeIsTeAUyosuoou)JosdyTT[eisip
yoru0o
oimssoidvIxoyoresoourqingsip
pooygqJopoziperouesormmouoyneeruoumoud(eTuourSSOT*SNOII‘doup1003JYst1‘doip1003
ASororsAydTenysr9qUr-nouduoronAtered*‘SSOUYBOMTYSLIYIMSIsJoye
qosuo
Sd)
pue
smojduiAs
ppeN/swodwAssaourqinisipuoomyeqqAqureyi90olowty,ArojerdsayomuouoinyQSINOSBSBISICyOsugOsheq
onsouseipSOpigiowossinjord[eoruryo
qurneaSgHDJO[DAV]sIsouseIpSGDSNOTAI61-GIAOOamjoidjeomipsSGHXOSasVAyyunozspnIy
(penunuos)1aqeL
od
v
50
|
‘S
a
Nn
ll

1139
1133-1170
Journal of Neurology (2021) 268
(swiojduiAs
TeorsoTornou
Utquar
-mouod)
eruoumoud
Tennsiaqur$39TesoVeyTIGUISSOUBOM‘eoudsAppyrurBIXoyoreSuIpusosepureysnoopozifesiouss‘SOrTWoa]x9JOJOULAap‘yeroyyyasuo‘AsjedoarouTnpureTT
-1LIOSUdSASojotsAydonosyaO10S8“IOAOysumoydurAsyeroeyIYSII[eIsIpUrssouJoye[St]Te39Issel1+JSO+feoQUONopeis-MoT=JoyesAep1ONQUON=Tedoydisodpry,-quuinupueulegSAep8]WOruel]Yyopezuiyelgy
uored
JoJoulonsyey-suodpureiudp
-1IOSUdSABojotsAydonos[ay‘ers[eAUSUIPIOAULBIXoyore-OT[e[eISIppurl
Issel1+4JSO+feoruyDQUON‘ysnooAqVNON—-SONITMOIC,pozipesouory‘sisoredeiegJoiesAep9WOL-Iozums—[Pp]]Te1us0g
OINIey
Aroyertdsar
(uonJejnosnwomeusourqSTLOY-ounjsAp‘ssouyeomWIE-INjsIp123JoJOuI-duidsjoormouojnedAIssousoidoatssarsoid
-1JOSUOSJosuo9U}poyroods‘ssouyrom‘ersoujsoviedJoye
oIssel)cHSO+[eoiTaVNJoaoJoyeskep67S94yOu)SOA[efovyTetoye[lg=JoaypuvSpueFysAep9TWv8wsn=[er]Teeueyp
SSOUROM
UOTXOyyoou
‘elaresAp‘eis
-vydsAp‘ssou
Rom[RTO]
[eroqeyiq“YTB
[99Y]JO90]OF
AYIIQRULILM
yes
Apeoysun
“‘elxopoleTT]
‘erxayarodAy
TN‘s90}9t}
qeosuos9A]
-dooordoid
sumo}pureAzo}BIsoujsovredJoJOuIsumojdurAs-durfsjo-BIGIAJuasqeyJoojpur
qosuo
Sd)
pue
smojduiAs
ppeN/swodwAssaourqinisipuoomyeqqAqureyi90olowty,ArojerdsayomuouoinyQSINOSBSBISICyOsugOsheq
onsouseipSOpigiowossinjord[eoruryo
qurneaSgHDJO[DAV]sIsouseIpSGDSNOTAI61-GIAOOamjoidjeomipsSGHXOSasVAyyunozspnIy
(penunuos)1aqeL
pringer
QS

1133-1170
Journal of Neurology (2021) 268
1140
ASojotsAyd[07]VNc-OFD9T9+TBOTUTT)VNVNVNVNVNVNWNJayeskep¢W0cBIpu]|
eumoydurdA,(poyreiop
JUBLIBAIE[NOTTO}Joujou)BIXopore[61]1819JOAZASO+eomyg-uaiodAHAroyerdsayyWNONWNVNspurerxeye1ieyskepST4tLuteds—Zopueuley
uotjisodpur
UOTIBAQIAJO
asuaspoonpal
purerIsoyy
-sadAy
dao0[3
-pue-suryoo}s
“TAau]1B
BrxoqorodAyJOJOULyosuopueTT]93
-1LIOSUdSASojotsAydJOAgypursumoydurAsyeeIxogoreyooyJoye
OIsseOZ-OI99[9+[ROUTyrod4iwa=evoudskp‘ysnog—sJoyesAvp1ONJUON,‘stsoredenay,jovlsayjsoviegsdepOTWlvue=[ST]‘Te39Ize
Bisoujsovied
Teqorzedpue
yensury‘Asted(uots[BLORyTeAOIeTIG
-STUIpeOU}‘erxogoreeuoumoudJoyeUfSp)[er9ue3
JOJOUL‘eaoudsApyasuo‘eiso[deraySqUITT79}UL
-1IOSUdSASojotsAydonosyapueysnoosuoyduds‘eiseydsApssouyeompureJoye[LI]1819
USTs
OnsesevT
oatytsod[ero
-JeTIQ‘eTxopfore
JOJOULpozteiouesSqUIT]fOU}Ut
-1LIOSudsSASojotsAydonosyasnyyseeuoumoud‘eruojodAyBIsoujsovredfot]IsselI+4SO+[Roryployeurnoyy‘y8nooAlcVNONQUON‘sisoredeyoy,puessouyearyJoyeshep¢4OLoOoDOIOE«=-TB39TURN[FT
(suioidwids
yeorsoTornou
UTMJUoT
-mouod)
ssunyyoq
ouy‘(poyTIpuevixoy=puressouyeom-1oadsjou-o10dAyTp)SOTITUUNAITXOJOJOULsuo}duiAs)yosuo‘SsoUyBoM‘TTInpueTT
-1LIOSudsSASororsAyd61-CIAOOsuo}dudspueT-)TeIstIpSuIpusoseJoye[st]Tew
yosuo
Sd)
pue
sumoydurds
ppeN/swodwAssaourqinisipusamjoqqAqureyi90olowty,ArojerdsayomuouoinyQSINOSBSBISICyOsugOsheq
oJsoUuseIpSolIprqiowios=sanjord[eoruryo
yuRLIRASqDJO[ANTsIsouseIpSqSNOTASIg61-CIAODamjordTeorul[asqxaIBVAxyunoz)apniy
(penunuos)1aqeL
pringer
QS

1141
1133-1170
Journal of Neurology (2021) 268
Asjted
darouyosuo
yeroryAsojotsAydysnoosumojdurAsJoye[97]Te39Teqaepig¢-O09[9+[ROTUT[DQUON,pureIoA9,JJoeAep|ONONuolssaldoidoNeIsoTdip[eroeyskepOT19uedgourwerdovryne
BIXopore
‘eisoujsovred
TATesereyiq*BIsou}AytsoqoayorpeoySSOUYVOMTT
-sovied]sseyopue‘eosneuqer9qe[IGSSOUBOM
yeroryASojorsAydonosya-aid‘uoTs‘eaoudsApsumojdurAsaraaas‘Asted-quinu[eroRyJoye[sz][eroyelaI+ASO+[Rory~uaqiadAH‘ysnoo‘Joaat—Jaqyeskep¢ONVN[erory[etoye[lepopis-1ystySAPPOL1cvsn‘TeJosuTyoINAL
BIXP]epuvys(UOTs“erxoyore
-STUIpeOU}BIXopore‘SSOUBOMJOJOULBIUSOUR‘BISyosuo‘stsorndeyo}oY)UlRISO}
-1LIOSUdSASojotsAydon-TeAw‘YsnoosumojduAsploory‘ssou-sovredpurJoye[rz]Issel1ofa+4SO+RomyQUONAIp‘Ioaay—sJagyeskepZSoxVN-yeomSurpusosy_BIsoujsovodAHskep¢]39BISny[Te19YoqIaH
(20RjI9UT
Toyshy
TOTAL
-Sap)(Asted
styertuesoJOAQ}opeisBIXoporesugonpge[R19[ez]1819stytmoudjogZASO+reoryoQUON=-AOT‘ROTTIRIG]VNONQUONpozyeroucry=-yeTIq)eidojdiqsaijeshep¢6¢ureds=zIQ-zaianny
BIxogore
pozijer1ouesBIsnose‘eTUT‘erxeye‘Asted-soue‘uredJOJOWIOTNIO
yorqMOTIe[NOLOSRISIBIXEE1BJURLIBA‘ayoRpeoypuestsoredour‘elsoujsovied
JOYsh]BUYS‘OsTeyeUL-[eujydoresoTedotiod‘erd[ez]1819JOTZASO+Teom1yypTetyouoig‘YBn0d“DADVNONQUON-nuIa}UTYs=-op[eorjJaAJoyesAep¢osuredg=zIQ-zalignny
ASorotsAydonBIXETe11s
VNT9979FASO+[PoyVN=BayLerp“eaa,]VNVNVNVN‘BIsayIsovledVN€sArey[7z]Te19YsIH
BIxogore
JOJOUL‘stsoredeqayTI
-1LIOSudsSASororsAydsuyeamsSUTPUdOSEOATSou]uluredJoye
yosuo
Sd)
pue
sumoydurds
ppeN/swodwAssaourqinisipusamjoqqAqureyi90olowty,ArojerdsayomuouoinyQSINOSBSBISICyOsugOsheq
oJsoUuseIpSolIprqiowios=sanjord[eoruryo
yuRLIRASqDJO[ANTsIsouseIpSqSNOTASIg61-CIAODamjordTeorUr[sSqIBVAxyunoz)apniy
(penunuos)1aqeL
pringer
QS

1133-1170
Journal of Neurology (2021) 268
1142
BIXEE
pozijerouos-sovred[e]sIp-oumnsud
‘(ersotdeqoy)‘stsoredeo}jouoJOJOULBIWISOOBOyosuouredSSOUYBOMdatssarsoid-njosar
BrxoqorodAy
pue‘erxeye
‘(sorsyedoarou
yerueio[A[ero
-]eTIq[enyUdA9
pureoArou
[eruetoTIT
yuerIVASUIpNoUr)BisoyjsoodAy
JOA¢TeorQUON“ST[IYO‘I9A,JWNONouOoN=-YydoaatssorsO1g-edouemjdg=toqeskepW9¢vsn[o¢]Te2somueT
BrxoqorodAy
pozijer1oues
uopsounouoid=—sT[BJJuaTIMOAT
ASojotsAydonysnoosuoyduds-eredJYsITs‘sts-yeomTTpue
JojOurIngTL098+489+[RoryQUONAlppueioaot=JayyesAep¢ONQUON,-aedTQWsTNWstaMoyJoyeskepZWSoAuewen)[67]Te19odweT
BIXopore
‘RIxeyees
‘sorTadxo
[eISTp
JO
BIsoujsovred
ye‘ssoueamJOJOULyosuo0}AjITIqeurpue[eutrxord
-1IOSudsSASororsAydsuoydudsSsouyeomQUIT]TeormourmtAsJoyespuryra
"ysnooArp
‘IOAO]opeis
-MO]‘UOT,vrxoqorodAyTT9u)Ur
JOJOUL-OOJUTJOR]yuajstsiadBisoujsovredBIquiy
-1LIOSudsSASojotsAydorosyaAroyerdsor‘yUOWIOAOIdUTpureerixoyoreJoyeIpnesjo[27]
yosuo
Sd)
pue
sumoydurds
ppeN/swodwAssaourqinisipusamjoqqAqureyi90olowty,ArojerdsayomuouoinyQSINOSBSBISICyOsugOsheq
oJsoUuseIpSolIprqiowios=sanjord[eoruryo
yuRLIRASqDJO[ANTsIsouseIpSqSNOTASIg61-CIAODamjordTeorul[asqxaIBVAxyunoz)apniy
(penunuos)1aqeL
pringer
QS

1143
1133-1170
Journal of Neurology (2021) 268
optsWsII
oy]UOssou
-JROM[RIOR]
“‘elxopgore
poziperouas‘IoJoulBisnoseBisoujsovred
-LIOSuasASojorsAydonosyapureerutsodAyTI‘TI<1NJoye[¢¢]
youriq
Areyrxeurpue
IeTNGIpueUl1J9]
OU]UTBISOyy
-soodAy
pyrur
pure‘sjoojap
[ELOR]IOMOT
plfur“erxopore
pozijer1oues
‘eLoulshp
euoumoudureroddn1J9]
yuerIVAqeraqeyIq(eTuour‘OZes[BIOL]BISouy
Joys]‘eIsnose-nouduorpure[eonJoAUl-sovsed[eroeyJoye([z¢]JOAZASO+[eoryDQUON‘Ysnoo‘I9A07VN-an0U09)soxouON—-vidoTdip‘erxerypueeidojdiqsdepOT4OsAjeyyTe19Moursueypy
ssou
-SNOTISUOdJO(soxoyaruopjosoposidaJoy1d90x9)
yuormMoolBIXoyore‘SSOTSTOM‘elsoyjsotfed
“SUTITWIOA-odAyar0A0s8
-IeIp‘eiseAUJomoy‘Asted
JoJOuITOAQ]‘soyoryosuoyerory[eroyeyiqviseydsdp
-1IOSudsSASojotsAydonosya-peoy‘ysnoosuoyduds‘stsoredejo}*‘SSOUIZZIpJoyepurl[i¢]
RISO
‘uredysoyoBIsoyisoodAy(er‘son[NOUyIp[eISIp‘vrxoyore-oumnsudJoJOuIsuTyeoqyosuoTNYopueTTJyeoyoyoujouonnt
-1LIOSudsSASororsAyd‘SULIOATYSsuo}duds‘stsoredeaquouted‘ssou-OSO1OU)purl[1¢]
yesuo
Sd)
pue
sumoydurds
pen/swojdwssoourqinisipua0mjoqqAqureyi90olowty,ArojerdsayomuouoinyQSINOSBSBISICyOsugOsheq
onsouseipSolIprqioulos§=—-aanjord[eoruryto
yuerieaSqnJO[OANTsisouseIpSqnSNOIAgg6I1-CIAOOoinjordTeorrpaSqxas38VAnunodpny
(penunuos)1aqeL
pringer
QS

1133-1170
Journal of Neurology (2021) 268
1144
BIXEE“BISOU]
-saoddAy[eIsIp
“‘elxogoleTTJOJOULJoyInjou)In‘stsor
-LIOSuasuonsoyutAIO}-ediipenb[S¢]Te39oISseTD(4ASD+jeomiTDWN-tuldsarroddyWNoNWNWNsulpusosyWNioiurl]yeurdryapyzoy]
BIXOp,BIsou}BIp-OIB[BGOTutaAstedJoyLInjou)yesuo‘AYTIGeyIsULsumoydurds[erory‘eIsouy
yeroryA8ootsAydonog[ouonooyutAIO}sumojdurAsainssoidJeqjng‘ssou-soviedTTJoye[S¢]Te39TeqaepigI+HSO+TeorVN-vaidsorsoddy)=JaqgesepgONpoolg-yeomTTPLADAISSAISOIGskepOTWgCuel]=yeuedryapyzoyy
BIXoporeBIsoujsovred
pozierouesJOsuo-[RISIP
‘JUUIDA[OAULUIISTSvoudsApyesuoSOAIOU[RTURIO-oredeyo}
NOYITMJOAwmoydurAspureeiseydsApoatTssousord[re]Te19WN¢TeoryTDQUONpureysnod=raqjeshep0]SohVNUWiMoatssasolgpueuredyorgsoyeshepg4OLuredsBMsuy-eIeAL
eido[dip
quorsuey]
“‘ssoupeom
[eroRyBISNase‘erxoyore‘erusodAypozijerouos
ASojorsAydonosya‘etmnsAp“1<1nJoye[¢¢]JoJouongI+ASO+peorVN‘Y8n0d“DABVNONVNWN__sisoaedripen?t)skepTZWwWOLAjeq][TeJoMIouvsueypy
-1IOSUdSASojotsAyd-soVUTOsespozijerouosJoye[c¢]IsselZ-onoa[a+[BoruVN‘YBn0d“DADVNONVNVN~~‘ssouyeomTTskep¢¢WwW+6Ajeq][TeJoMIouvsueypy
SSOUBOM
[elorj“eIsatyy
-saodAy
[BLoRy
‘erdoydip
“‘elxoporeBisnosepozijerouosyuerieapureerusodAyeIXe]eQUIT
TOTTII+ASO+RorVN*YSNn0d“ToAa]VNONVNVN-[euydoSAePFL46rAjey]‘Te39Moursury]
BIXoporevisnose[eqoys‘eisJoJOuIpureerusodAy-oujsovred
-1LIOSudsSASororsAyd‘eoudsApTN<TIJoye[¢¢]
yosuo
Sd)
pue
sumoydurds
ppeN/swodwAssaourqinisipusamjoqqAqureyi90olowty,ArojerdsayomuouoinyQSINOSBSBISICyOsugOsheq
oJsoUuseIpSolIprqiowios=sanjord[eoruryo
yuRLIRASqDJO[ANTsIsouseIpSqSNOTASIg61-CIAODamjordTeorul[asqxaIBVAxyunoz)apniy
(penunuos)1aqeL
pringer
QS

1145
1133-1170
Journal of Neurology (2021) 268
BrIxogae
pozijerouos
‘Asqed
[eroey
Tedoyetiunpue
‘eIsayjsosAp
“squiT]
[[eUr
(eru
SSOUBOM.sumojdurAs-ournoud
-1IOsuasASorotsAydory-noud‘ysnoosumoydurdspodojaaop‘stsoredered-mouod)[g¢]oIsse[-09[9+SO+TeorVNpursonnyJayeskep¢]ATOATSSOISOIgproorpyJoyeshep199ATRayTe39TURTARIIO
ssou
-quinupur
JOJOWvruounoud.SSOUyROMTTvru
es
OIxEyRJooJYI
UrssoyATOsuas
juopuodap
-YISUd]dIOAOS
Ajoyerapour
“‘eIxogoleTT
‘erxaouodAy
Tn‘ssouyeomuoeIpel
TRHYsIOVUTTewrxordpueorovIOUyTesoqe[IGTn[eistpaeJOMOTWOAISJOJOW‘ertusoue-JOPpOW/P|LU“‘QouR[TequIT
-1IOSUdSASojotsAydonosyaJNOYIIMVIS‘ssouyeoMUOT‘stsoredeiedJoye[9¢]
BisoyjsoodAy
TeormourmtAssays‘erxogoreprloyeumnoyszpozifesouesJOOULpure‘uotIsPIsRAUL“‘ssouyeomTT
oIssel)+ASO+Ror‘waAlp“IoAaJVNVNSAISSOISOIgSAPO€99ue]=yeuediyopyzoyy
voudsApBIsoyisoodAy
dAIssausoidTeormourmAsJoJOuI‘e1s[eAUl‘erxopore
-1LIOSudsSASojotsAydorosyaTOAQ]pozijerouedTIJoye[s¢]Te19
yosuo
Sd)
pue
sumoydurds
61-dIAOD2lIpeNnusomjoq0}SUIT],9SINOSsRaSTG,yosuoOsheq
SolIprqiowlos==sanjord[eoruyo
yueuRaSqDsIsouseIpSqSNOTAMI61-dIAOOomjordTRoTUITSSqIsVAzyunozspnsiy
(penunuos)1aqeL
pringer
QS

1133-1170
Journal of Neurology (2021) 268
1146
xXopores
yuosqeAT[er19
“eG
“AyTIqeur
SUTMOT[RMS
“eIxopare
pozijerouos
‘yooods
posints
UOTIOJULAyryiqejsutSUT[OOIpUIABIsoujsovredIoJoulyorAroyerdyesuoommssorddoosp[e1oeySuIpusose
-LIOSuasASojorsAydonosya-sarJoddnsumojdurAspooTqpue[erAIe[Iq‘BISoatTssousordJoye[LF]
ssoursumnoJOJOULBIXEE‘SSOUBOM
-1IOSUdSASojotsAydonosyaAlosuas‘ssou‘ssouquinu[or]orsse[)I+ASO+[RoryWNBaysielp‘ysnoDVNONSUONROM[RISTPPITALquit][eastq]JoyeSep17W8ean‘TRJoUOSIO}e
SSOUROMJEG
~[nq
pur
[erory
‘ermmouoinesAp
‘ssoyAlosuas
JOJOULBItUsoURyosuo‘erxogore=:SsouRampur
-1IOSUdSASojotsAydonosya‘eIsnosewo}duASpozijer1ouesssouquinuor0joq[or]IsselI+ASO+[RoryVN‘oyoepeopRy=JayesAep¢SoSox‘stsoredeyay,quit][BIsICAep|WwW09wn[Te19UOSIAeg
viseydsdpBItUsoURsso]Alosuas‘SSOUBOM
-1LIOSudsSASojotsAydonosya‘eoudsApwo}durAspozijeroued-quinu[or]IsselI+ASO+[RoryQUONJOAg}‘YsnodJoyeskepOTsoxVN‘stsoredeay,qui][eIsIq.JoyeAep¢]WwWTrwn[Te19UOSIO}eg
BIxogoreBIUDUISB‘SorJOJOULpruoumnoudyosuopozi[esouad‘sts-[NOUgIpwes
-1LIOSudsSASorotsAydon‘ysnooAIpsuo}duds-oredeyo]‘ssou‘eisoujsovredJoye[6¢]
yosuo
Sd)
pue
sumoydurds
ppeN/swodwAssaourqinisipusamjoqqAqureyi90olowty,ArojerdsayomuouoinyQSINOSBSBISICyOsugOsheq
oJsoUuseIpSolIprqiowios=sanjord[eoruryo
yuRLIRASqDJO[ANTsIsouseIpSqSNOTASIg61-CIAODamjordTeorul[asqxaIBVAxyunoz)apniy
(penunuos)1aqeL
pringer
QS

1147
1133-1170
Journal of Neurology (2021) 268
JURLIBA
JoUsty
JOTTNAL
JOJOUL
-l10suas
Issel
JOJOUL
-l10suas
Issel
I
-oog[a+[ROlUr[?
UOTJOOJUT
yuarMouos
‘uredyorq
oruoryopur
‘qurorpuAs
839]
SSOTISOT
‘erumaprdyy
-lodAy
ASojotsAyd‘UOIS
-uoyodAH
ASojotsAydonosya
+ASO+Teor)VN
ASO+[RomMiTaouON
STROMS
1stupue
“sT[TYo“TaAaJ
‘eiseydouApo
“BouIOUIyYy
euoumoud
‘ysnooAIp
pureonsney
poyzeurWTA
smojdwiAs
OI[-Np“Tea
sunenjonyy
uOTOSJUL
yourAroyerd
-sozgoddn
josuojdurAs
uorljugj}or
Azeurm.
purvip
-reoAyoryWNSohSUTISOY
yesuo
surojdurAs
JoqgeskepS]SohQUON
yesuo
suro}durAs
JoyeskepZONQUON
SISOd
-edowyeujydo
pif‘ersoydip
[eroey‘erdoydip
uonesues
suruing‘erxoy
-ore[eIues
‘stsoredejo}
SUIpusOSy
stsored
[esso[sodAy,
pue[erory
[esoqeyiq“Squat$JessoyAOS
-uasajoTdw09
‘eiso[deray
WIMouoIpuds
UI-Ppoyx0T
yeroydrioed
aoduos
JsOWyeURO}
uOTIBIOLIOOp
“elxapore
pozijer1oues
‘stsoredeay,
BIXETe11e3
‘syurofMoqjo
pureopue0}
dn
squiqy
[eastp
TeUrUoTEsuas
UOTJBIGIA
pur‘uontsod
‘yonoy1st
peseatoap“TT
UIJUasqepue
Tp)Ulsoxoyor
uopusydoap
oaTjovodAy
“ssouyRom
TT
[eistp
pue[ewrxord
pit
T1H0
roy
seisoyjsoredTT]skepp]W+Svson[ep]Te30euey
BIsoyy
-sovred[eroe
“ssouyRomJoye[Zr]TTpueTnsdep+]W1SAueuriony"Te19UIOIAyag
SSOUyvomMTT
-soredripenb
SuIpusoseJoye[ir]
DATSSAISOIgsep174valuel]‘Te19yseqheg
yuRLIRASqD
Ayurey120
onsouseip
JO[DAV]
SOIIPIGIOWOS
sIsouseIpSGDSNOTAI
oimord
jeoruyo
61-dIAOD
orn
[Tey
/swuoydutcs
Aroyerdsayy
0]OWT],
soourqinysIp
onmouoiny
9SIMOOISBISTC
yasuo
Sd
pue
surojdurAs
61-CIAOD
uaemjoq
yasug,skeq
oinjordTeorrpaSqxasa3sVAqyunozpny
(penunuos)1aqeL
pringer
QS

1133-1170
Journal of Neurology (2021) 268
1148
BISOysO
-[jedodAypue
BisoujsoodAy
“BIxoorePozieruournoud-[eroues‘Asted
‘eoudsApTeraLI[eLoRyJOJOULSOWITJOUIOSyosuo‘stsorndeyo}
IsselZ-onoa[a+[eoruly)zodiWaJOAAlJayeskeppONQUONSuUIpusOSyBOM[RISIPTTsepF]WwW69UPI][Te19Jeysepas
eIXopore‘JUS
-Jea]yf]Jo
uonenruruodn
yuowrsaordtuitSquIT]
queLIeaASojotsAydon‘eIsnosesumojdurAs-edeiedou]Jo“TTJossouJoye[i]onorederegL-09J9+4SO+4[RoryQUONAverodwoy,sageshep7]ONQUONSUTUOSIOM[RITUT==yBOM[RUUITXOIgsdepTI4+SAueuliory"Te19[plsyos
stsoredeyay
yeurxoid
O19A98pure
SSOUYBOM
Jeosudreydoro
‘Asjedoarou
“eIxopore
JOJOUL‘eoudsApyosuo‘SSoUyROMYJoqUlBIsoty
-1IOSUdSASojotsAydonpueysnoosumojdurAsSuIpusosepur-sovredpueJoye[97]Te19IsselL-09J9+4SO+4[RoryVNAIp‘Ioaay=JoyesAep¢SohONuredsequin]ssourpeo}sur)skepST49Suredg=vuepres-oyours
BIxogore
pozijer1oues
‘(e1so]dIp
SUIT]
INoJ
[BLOBy)SoATIOU78BIsoysoredBIsnasepueyetuesioou}Jo[eISIppueJOJOULBIWUSOUR‘BISyosuoJUSUIOA[OAUTSSOUBOM
-1IOSudsSASororsAyd-TeAur‘oyoesumojdurAsUIstsoredQUIT]OATSJoye
IsselZ-Oog[9+[ROTUI[DVN-peoyIoaayJoyesAepOTONQUON=_-vaedSuIpusosy-SAISO1gskepLIW+09ATeyy[Sp]‘Te19BART
BIxogore
omssordpozijeroueduredyorq
pooygq214‘Asted[etryJequinypueJURLIBAysnoopueyosuo-BysunpueTeroqeyiq‘eid[esdop‘squiry
IOYstyASorotsAydonviseydoudposuo}dudsBouLeIp-O[dIp‘erxeyeINO}[[eUrJoye[rr]Tey
yosuo
Sd)
pue
sumoydurds
ppeN/swodwAssaourqinisipusamjoqqAqureyi90olowty,ArojerdsayomuouoinyQSINOSBSBISICyOsugOsheq
oJsoUuseIpSolIprqiowios=sanjord[eoruryo
yuRLIRASqDJO[ANTsIsouseIpSqSNOTASIg61-CIAODamjordTeorul[asqxaIBVAxyunoz)apniy
(penunuos)1aqeL
pringer
QS

1149
1133-1170
Journal of Neurology (2021) 268
BIsoyy
-soviederxeyeAros
yeroryASojotsAydonosyasissumoydurAspozijerouesJoye[zs]
[elne‘uors
-uoqiodAySSOUYBOM[eloLe‘stsonsuoy‘orseyd
-O[NOTIOAIP-SAp‘SSOUBOMJOJOW‘axonsvruowneudTeloey‘erxopore
-1IOSUdSASojotsAydonosyaOTUIOYOST‘eIsnose‘eiso[derayBIsoujsovred[zs]
RIxoyoue
pozijer1oues
‘elsaysosAp
TI‘osuas
UOTIBIIA
pueyouduid
0]UoTRsUaSysnoopoonpal[eIsIpJOJOUpureoyoepeoyyosuo‘eISo[dIp[e1oey
-1IOSudsSASojotsAydonosya“‘qyeoiqJosuoyduds“SSOUyROMBIsoysoeJoyeWOpsUury,
osngevip
Joyooresuo}duds-reoAyor}
pureuolsAroyertdsar10puruoIsBIsoyisoodAy
-uayradAyJOAQ]NOYIIM-uoqradAy‘erxopore
JOJOU‘oseosIpSTTEyopuryesuoUaSur‘stsoredouyssou
vIxoyore
“ssoupjRom
gposnupeered
TYBTIs
‘sIsar
puresyoeproy‘Asjedpur
‘ysnooBisoujsoviedTIJOJOUuoIsAap‘yeoryyg0udupeloey[esoqeyiqpueTQwoq
qosuo
Sd)
pue
sumoydurds
ppeN/swodwAssaourqinisipuoomyeqqAqureyi90olowty,ArojerdsayomuouoinyQSINOSBSBISICyOsugOsheq
onsouseipSOpigiowossinjord[eoruryo
qurneaSgHDJO[DAV]sIsouseIpSGDSNOTAI61-GIAOOamoldpeopsqnAyyunozspnIy
(penunuos)1aqeL
pringer
QS

1133-1170
Journal of Neurology (2021) 268
1150
BISouy
-soodAy[esp
TI‘erxopereIoJouleruoumoudyesuo‘stsoredeo}
-LIOSuasASojorsAydonosyaysnooArpsumojdurAs“SSOUyROM,or0joq
oIssel)I+ASO+RomWN“(Oo7-8€)JAA—JoyeskeppONouONSuIpucosySSOUROM"TTShep84d19eur—-[9S]Te19ORY,
viseydsdp
eruoumoud“TTUlBIsoyy“eoulIeIp-satpedodAy
siseLiosd‘asTe[eUrBisoyjssodAy-saesfp100}JoJoulpuruoIspurvisTeAuryesuo‘eIxogore=pureSsoUyeoAA
-1LIOSUdSASojotsAydonosya-usyiodAy‘oupoepeoysumojduAspozijerouesquIT]SATSSoIswopsury
(jesuo
sumoydurAs
joskepZ
yasuoJour)
Sad
s710}oq
orulfo
skepZquojedjnoBIXoyore
-1LIOSUdSaployfip‘ysnooAIp-eyuasoiduoTUaqar‘ssouRomssouquinu
oIssel)€oy=wmpiasoj—“(ATOL)JAAJorgeApOYSSohABUL)Supusosy=‘ssouyBomTTJoyeshepgWvsvsn_[rs]Te39tue,
BIXoyore
pozijer1oues
‘erseydsAppurBIXETeWes
sisored[etoRy‘squiy]+9U)JoJoulTeroqeyIqUTAjossouquinu
-1IOSUdSASojotsAydBrIuoUlUOTSSTUIpeSsouyeomoy}puressouJoye[es]Te39OIsseOZ-oMoo[9+[BoutWN-noud‘ysnog=:Jayeskep7ONWNjoUOTSsoIsOIg-yeom[BASIC]sdepOTWcruredsUPTeDSOARS,
viseydsdp
“‘elxopare‘ssou
-JROM[eIOR]
JoJOuIeuoumoud‘eiso[derayBISouy
-1IOSudsSASojotsAydon‘erutsourpur‘ssouyRom-sovredpue[zs]OIsseOLT-09]9+469+[eorult9VN_Bisnose‘ysnodVNsoxQUONSUIpusOSyssouyeomTTJoyeskep7W19Ajeqy‘Te39OUBDSOL,
BIXEEJoJOuIyosuo‘erxopore
-1LIOSudsSABojotsAydonos[yqvrursodAysuo}dudspozl[eroues‘STsSSOUYBOMTT[zs]OIsseOI+4894+[RomoVNpueysnog=JoyesAepONQUON-o7Tedem9]prlooepy‘urediequiny=iaqyeskep¢WOLAjay‘Te39OURDSOL,
ssouSSOUyvomMTTJoJOuI-yeom[eIORy‘squIT]+9U)
-1LIOSudsSASojotsAydorosyaeruoumoud‘eIxayjore‘sIsarUTseISoysoJoye[zs]
yesuo
Sd)
pue
sumoydurds
pen/swojdwssoourqinisipua0mjoqqAqureyi90olowty,ArojerdsayomuouoinyQSINOSBSBISICyOsugOsheq
onsouseipSolIprqioulos§=—-aanjord[eoruryto
yuerieaSqnJO[OANTsisouseIpSqnSNOIAgg6I1-CIAOOoinjordTeorrpaSqxas38VAnunodpny
(penunuos)1aqeL
pringer
QS

1151
1133-1170
Journal of Neurology (2021) 268
(ISD
pur
WIMnJasUIYO)
spurq[BuO[O3ITOdolp100}14311pueuoTe[UGAjosouasaidyO
d0udjstsrod‘Stuy-sooyors+qeuinzsosueyooaTyesou‘(QL1)UTUING]eWNIOSMOT
-durdssatqeqasoa-T[I90}‘Advroyy
oruosomnouonelurTuIng]e/3]sorpoqnue‘stsoyAo0ong]‘LOD
joyuowlaaordut[eaqlAojoIUe(skepS)JeTNOsNU‘TeuOXRPoSvarTOUl*[9AgToptsorsuespueHa’paseorout
‘QTA]JoyesAepsg=‘outnboropyoAxorpAHSy/3UlOOFOTAIWNAJosuasJOO,«=UTAJOId[10][PUTION-TJUROATIESON,‘etuadoyA00ydurh’'TLO18940+WOd-LY[3]Te19TIssy
(ISD
pur
WIMnJdsUIYO)
spurgq[euoTIOsT[OwsuanspurestsojdjosouasaidyO
onsuoy‘yooadsTeoruvyooul+ITAeuoaTyesou“(¢¢Z)UIMIOSMOT‘sIOyeUI
‘SUIMOT[EMSJO-1doypurIAeuojt4
ssulpuyddIvonerurwmngye/p3y]UOTJBUUUBULpue
yuowloAordut‘topiqie‘surnb(skep¢)Teorsofoujedsutzeds[emsPoSVaIOUT*[9A9THdpaseoroutr
‘TAIJouesAep¢-oroTyoAXxoIpAHSy/3UlOOFOTAIou‘UreIg=mSuyeurpoAMaq]«=uTajoid[v10][PUTIONWN‘etuadoyAooydurh’'TWOd-LA[3]Te19TIssy
YOod-La
AWDpurAdaASojorasAGT
aanesouYd‘AWD‘sitydas
TeuOpSOSITTO9adANRSOU‘SoIpogouTOAUT-edou‘stsoyoodayd-yue[emmounueyuowloAordut-OIUJIZE‘SWITXIOJIO(skep¢)ddIvou‘(7/8$9)uraypuroprsorsues
DATSSOISOIg‘umboro[yoAxorpkHLB8yY/3UOOFOIATWNsuneurpAwog-o1d[e10]posvarouy-TWURDATIVSON,WNLO18999+YOd-1LY[ZL]Te19pneury
dod
CA9ID-SUVSommypreyAroyertdsarUONLINUASATSBAUToAnesoU“TH/ST[IOjoosneoaqyeopoulnboro[yoAxorpAy,Teoruvyoour+(skep¢)ddiv6‘(1p/sur7s)uray
UOISSTUIpeJoeUYPZTTABUOFLI/TIARUIO'TB8yx/3UOOFOIAIVNsuyeurpoAmiaq]=-od[#0]posvarTOUyTVNVNLO18909+WOd-LY[9]‘Te19WaoqTy
stsaroydomsao
urajoidwintaspure
C1[ewtou“ATH
‘gqpueVsniiA
‘pI4aquaDIJIUOU
-]DS‘aniuouneaud(H/01
pusvjdookyX7E-L['Tsonyeasoua
‘quntal4aja0q~rgyjor“T/OLXSr)
-ojkduIDZ)IO}
vruodoyAooydurdT
ToOI/cSulusaios2AN)“CT/OTX00€-STI
SuowraorduyJOU)ssnIp[eIAnUYyAep/sx/3uOOrOTAWNSuTyeUTPOAWIOC][e101posvoroUy-WuURe“VWNVoAne30N,vruadoyAo0quiomyy,LO18949+WOd-LY[s]Te19nsosy
adAiqns
orsoyorsAydonsasneoSqH6I-CIAOODsqo-9919SHpureodAyWOUNDSOUL(jeurdsAuyedomaoyy:A8oJo}SuTUseTOspur
sUIODINOAdvroy]pueyuowseuryy=pureUTeIq)[YIN-jorsAydonoo,yssulpuy4SOsorpoqnur-onyssulpuypoolg_sTsouseIP6|-GIAOOpny
(penunuos)1aqeL
pringer
QS

1133-1170
Journal of Neurology (2021) 268
1152
a
soo
-edaypure‘ATH
“q3VSIA
ezuanguy‘AZA
‘CLASH‘Ada
‘AWS‘bolreque
RTOUOWTeS
‘apiuounaud
‘urredoyWYystom-usa10ssaTesOU
IE[NOB[OULMOTUONLINUASATSBAUT
yunod[][99[euIOU‘sorpoquue
‘TourejoovledTeoruvyoour+(skep¢)ddiv‘(7/899°)wrajoadsoprsorsues[Lt]WN‘Aderay]UashxOS3y/BUlOOFOTAIWNSuTyeUTPOAWIOC][e101posvoroUy-TWURDATIVSON,WNLOSI+YOd-LYTe19Byouessopuresd
“qw/sd|1)9-TJo
“BIpoTIOguoneagye‘(¢¢>Tewpueseruoumoug-I0U“T/A.LPS
purse[doodjypure6rS)Ldpue‘AIH‘AWDLOD‘(87>[ewWI0u‘AZA‘AGA“T/Np87)HAT50
oyeoTonuoydiourumospur[eutiou“T/,01X89-0)-Aqod‘uru/sT[2oHSOuosunsaqvruad-oyAo0ydurATBISo[CIp[eroRy€]JUNO[90OISOTOTGOIONU“(¢'Q>[eWOU)Tpjoyuouldopaaopposearourpue(TpATIRSOU‘soIpog/8uso‘gdao
‘ssouyRom‘TTpurTlavunsep“ITARUOTI(skep¢)ddIv=/8WSpz)wraqoad-TyUvoprsorsues“(Spl>[ewuou“T/)(LOys949
Tnjoyuowmsaoidmy=‘autmborzopyoAxompAHS3y/BUlOOFOTAIWNSuTyeUTPOAWIOC][e101posvoroUuy-TWURDATIVSON,19b)MdOpoweaoly,[ewou)YOd-LY[OT]Te19vrpseorrg
Od7-APD
-SUVSoanesou
“TOX9*JunOSsorpoqnueyuowoAordut(skep¢)ddiv119°‘(7/89'T)urayoptsorpsues
dATSSausoIdMOTSWNS3y/BUlOOFOTAIWNsuyeurpoAmiaq]=-od[#0]posvarTOUyT-TWURDATIVSON,dOposearouyLO18949+WOd-LY[6]Te10nesIg
(SOAIOUJITA.
‘TI
Ut)
stiinou
Tetueioadn
-Tnuw‘snxatdWOd
IequinypueT-A9D)-SUVS9A]ASojorasstprydds
TeryorrqU0-e8ou“T/,O1XTpurowd’y‘AIHUONRNUGASAIS~—-UOSTTXaTdpue:JUNOD[90ATIVSOU‘soIpog
yuowoAordut-BAUI-U0U+(Shep¢)SIUTNOIPeYddiv‘(1/8$60)wrajoid-TjUvoprsorsuesduosanesou
DATSSOISOIgWNS3y/BUlOOFOTAI‘jeurdsSuTyeUTPOAWIOC][e101posvoroUy-TWURDATIVSON,‘JUNODPOOT[RWLION,LO18949+WOd-LY[6]Te10nesIg
adAiqns
orsoyorsAydonsasneoSqH6I-CIAOODsqo-9919SHpureodAyWOUNDSOUL(jeurdsAuyedomaoyy:A8oJo}SuTUseTOspur
sUIODINOAdvroy]pueyuowseuryy=pureUTeIq)[YIN-jorsAydonoo,yssulpuy4SOsorpoqnur-onyssulpuypoolg_sTsouseIP6|-GIAOOpny
(penunuos)1aqeL
od
v
50
|
‘S
a
Nn
ll

1153
1133-1170
Journal of Neurology (2021) 268
THCA2atover
-uou‘ADH“(d
puevyodAq)
(Jp/suOL)SNJIAeZUONUI
gsoon[sTeuou‘AWO‘ADA
sepOTou:yeurds/Q=A001AI)JoySurmsa10sSISOIJoyeTeWoUIeoussulpuyyunod[][99[euIOUSATIBSOU‘SOT-oydoxoo[20UNIT
0]WsuaNssposnurTeorsoroujeddqdiv=‘(7p/surgz)ura}-poqnurqIOyurajoidwnJas[eULIOU[sujoyuouraaordwysumnboro[yoAxorpAHJUONou:uleIgsuyeurpoAmioq,§=-0ud_[#10]posvarToUyT-ueoanesoN‘(T/SUIS$)YO[eULIONLO18949+WOd-LY‘Te19Yopezunnyeiq”
Wd[oued
ZT-AOD-SUVS
20
sHeydeouaystis
woreTIqeyoyyssulpuy-edou‘sisoyjuAs-UTUDUTSATIVSOUuoresteiidsoyTeorsofoujedddIv8][eooujenutou‘sorpoqnuewoTTAepWor(skep¢)ou:yeurdssutzeds[ems‘UOTIVIOOSSIP[BOsoprsorsues
“yuowoAordunprdeyS3y/BUlOOFOTAIVNcureig)=YumSuyeurpoAmoq,«=-T8ofo]AoouTUNTy-uecanesoNV=(potoadsjou)[eUTIONASO[OINS+WOd-LY[PL]Te39ua0g
ToyeHUSAOd7-APDoY]WOpoursm-SUVSoanesouATMOTS‘UoTOUNyOTA+(uonepuaa“Tp/sulg¢asoon[s-sAportmouojneUOJH9UNqINOYITM)SIs‘WIUI/ST[20J
JUO}TULIOIUTTMA-oroydeurseydJosuots:saqAoo0ong]‘(Tpsorpoqstsorediapenb-S9S¢+UOTIRTUIA/sw£9)urajoid-TWURPS]/Hs]
joJ0Ud]STISIOgDATSBAUT[ROTURTYPOJATVNVN[e101posvoroUyZIADporeacly,VNWOd-LA[eT]Te19ueyD
Od7-APDyesuo-SUVSoanesousmmoiduAsJoye‘Tp/SUlQS:3S800skep87s0uR\sIssessulpuy“NYS*WIUU/STI99€
-eEynquie‘eiseydstsozoyd.ou:ourds/8WI9ZZ)UtojOIdsoprsorsues
-sApJoUoTNOsayy-vurse[dJOSUOTSSas¢Teroesoquin’y]VN[e101posvoroUy-TWURDATIVSON,VNWOd-LA[eT]Te19ueyD
wd
CA9ID-SUVS
oAnesoU‘(TeUT
Bisoujsovied
yuowoouRYyUS-I0U)T/,01X+(T/s8W{7[)JowWIp-a
posueyoun‘ssouSAIOU[RTORY:UNOD[90payeagye“(T/,O1X889“Jeo[RIOR]JO(skep¢)[elueioeulddiv‘(7/800'1)weoidOdWMNWIXRU)stso}
quowMAordunWSSurloAuroryizeondunySY/sUOOPOIA—-[ese]IqsurergSuTyeUTPOAWIOC][e101posvoroUuyVN_—-Ad0qWOIY]JUOISTSIOgLO18909+WOd-LY[ZI]Te39ueyD
adAiqns
orsoyorsAydonsasneoSqHsqo-9919SHpureodAyWOUNDSOUL(jeurdsAuyedomaoyy:A8oJo}SuTUseTOspur
sUIODINOAdvroy]pueyuowseuryy=pureUTeIq)[YIN-jorsAydonoo,yssulpuy4SOsorpoqnur-onyssulpuypoolg_sTsouseIP6|-GIAOOpny
(penunuos)1aqeL
pringer
QS

1133-1170
Journal of Neurology (2021) 268
1154
NVAV
AI9A0004VNOIAIVN[BuOxYyVNVNVNVN[Oz]‘Te9JosOISUL]
solpoquur
Oprsorpsues-yue
UOTJBIOOSSIP[BOJoyjOsaTesOU
ssulpuy-Is[0]A00uTUING]e‘sompoq[61]IIAvUOTTI/MACUTdOTTeorsofoujedVN‘(7p/8tOTT)ue}-yueqIdy‘Te19ZonsuNWOgVN=‘outnboropyoAxorpAH(sAepS)Aep/307DIATou:uleIgsuyeurpoAmiaq]=-od[#0]posvarTOUyT-TWURDATIVSON,WNWOd-LA—Zopueuloy
Yu69ASA‘dado
JOSTQA9]poyeagya
*(%6ST
:o1Ao0ydurs]owi0ojnooummbor‘6g:sprydomnoua[qeioary‘skep¢-o[yokxorpAypur(shep¢ddiv“TOIX6'S:O8M)
JoyeuouToAoIduyTIAvuoTI/LAvUIdo'TIOA03H/3Z)OIAWNSuTyeUTPOAWIOC]WNWNviuodoydurk’'TLO18949+WOd-LY[ST]Te39Ize
Ip/3
g°9
uesouLIgLy
‘1P/SWPOTTAD“Tw
outds
/8UprsUNIO]“Tur
[TROLAIOOpue/8U9¢¢JOWIG-a
BisoyjsovredUOXPLDJIOyuoursouRYyuS:JUN09[99“(TP$]S9}‘Ip/8pl4Hwu
joa0uajstsiadnqUTOATWIOIYIIZE(skep¢)TeosuruSuIOYddiv/8W9g)urajoid[eIIApur[BoIsoT/00%TsAo0ydurAT[£1]quowdAoIdunJojopy==‘eutTnboroTyoAxXoIpAHAep/sx/3uOOrOTA-doy:urergSuTyeUTPOAWIOC][BJO]pasvarouy«=-olTajoeqeaRsaN—SUI/QOP,aAO0oNAT«ABI-XISAO+YOI-LATE19BUTPOP]Uegaysy]
SUYSZUs‘AepJoyAvsseyUOWIOAOIdUIT[eoJsIQoY}JeSUIOOSWOdsanesou-IZ0TOINIUJUROUTUuroAtuoryyize‘AepNVSINV=‘Juno[]90[ewWOU
-3ISOUUOISsTUIpE/8UIYQ9ouINb(skep¢)[euoxe“(T/81)utojord({UI/07ZS)
WOIJ|JOOMIV-oro[yoAXoIpAHAep/sx/3utO0rOIAWNAIOSUdSIOJOJ[[e101posvoroUyWNviuadoyAooydurdTLOowssyo+yOoa-LY=[OT]Te19tueuno1
TRICA2aToRar
“wou‘ADH“(a
puevyodAq)
SNIIABZUONYUt
‘AWO‘Ada
dajopqojkduiny)
seppIJoyeJoySurmsa10sstsazoydonoo[souSOTTOXO[TeULDATIVSOU‘SOT-NUIWITULajordwindas
yisuenssfosnuuddlv-poqrueqiOD[ewsou‘(T/swpe)[st]JoquoweaordwyVNOIAIVNsuneureduoc]VN“HuroanesaN=dupareagyeApysiysLO1899+YOd-La‘TRJoYopezwityesiqy
adAiqns
orsoyorsAydonsasneoSqH6I-CIAOODsqo-9919SHpureodAyWOUNDSOUL(jeurdsAuyedomaoyy:A8oJo}SuTUseTOspur
sUIODINOAdvroy]pueyuowseuryy=pureUTeIq)[YIN-jorsAydonoo,yssulpuy4SOsorpoqnur-onyssulpuypoolg_sTsouseIP6|-GIAOOpny
(penunuos)1aqeL
pringer
QS

1155
1133-1170
Journal of Neurology (2021) 268
SoXoyorUOpUd}
doop[eurioupur
‘syuowaaoul2X9
oj0[du09‘eIsnose
OUYIMAIOAOOII
Od7-APD
-SUVScanesou
‘Tp/SurYS:osoon{s
‘(soyAOOUOUL[[B)
Wz‘OAs‘CIP
Teorsorornousjo[d/s8w79)urlajoid({i/sT[20[¢z]-W09IAL]SYIIMZjourrjoovlegQUONVNVN[B}0}]pasvarouyVNOOT¢)eruodooneTWOod-LATe39ZHIQ-zeriannyH
dod
T-ACD-SUVS
oanedou
BisnoseoaTesou‘[p/su79sorpoqnue‘erursourjds0xagsoon[soprisorfsues-nue
uornyposarajoTd‘sayAo0ong]ou“(TpJoyo‘sorpoqIp/SU8°Z
WOIZSyIOMJIOVVN3/8OOFOIAIVNVN[B}0}]pasvarouy-WUESATIISOgOOOLso1Ao0yduATWOod-LATe39ZHIQ-zariennyH
dod
7-A9D-SUVS(qeas[eseu)
DATIBSOU‘Z-A0DSOSNIIAgpue
-SUVSJo}8]VYBZUONUIJoy
oatitsod*qH/sT[99WOdsanesou9°Z:sayAo00ng]‘soipoqnue
ddiv‘(1/sut3°61)urayoprsorfsurs(HOd-LYeanesou)
WNWNWNWNsuyeurpoAmioq,§=-0ud_[#10]posvarIOUyT-TWURDATIVSON,WNASOTOIIS+L.DIS9UD[ZZ]Te.19WsIH
STLILA
evAunsunyIYDpue
SnilAonsusq
‘Ada‘AWO
‘CASH‘TASH
JO}YOdsanesou
WOd7-AVDssulpuy-SUVSoanesou
Teorsofoujed‘AISTUIOYOOIGSOou:yeutdspuryunoo[[90[eur
pojstszodgfozepuaqyessulpuy-I0USULMOYSYI0G$189]THCApue
SSOUBOM‘JUSTUTOATWIOIYIIZE(skep¢)TeorsofoujedNVAVqredesyoom7AIH‘ODpuegq(NEYpue98))
-QAOIdUITSUS‘qUOTOSTUPoIdTAUIOJAAep/sx/3uOOrOTAou:uleIg[euoxysiskqeueFSOomy,suedoyoanesonN=[eurouqyOpureOMASOTOINS+“YOd-LY[LZ]‘Te39yueLy]
adAiqns
orsoyorsAydonsasneoSqH6I-CIAOODsqo-9919SHpureodAyWOUNDSOUL(jeurdsAuyedomaoyy:A8oJo}SuTUseTOspur
sUIODINOAdvroy]pueyuowseuryy=pureUTeIq)[YIN-jorsAydonoo,yssulpuy4SOsorpoqnur-onyssulpuypoolg_sTsouseIP6|-GIAOOpny
(penunuos)1aqeL
pringer
QS

1133-1170
Journal of Neurology (2021) 268
1156
(asoq
Atoyeroge’T
yorRasayoseo
-SIC][ROIOUDA)
strydAspue
‘CAB]pur3])
ung
‘(A8]
pue pyas4og
“(WB]
-oumaudpuspjid
-oo8W
“CINS])
[eorsojoured8]7/1ASH
ou
:jeurdg
‘T/LAIH
‘(O81)
OATOUJojdooerp-url0d
JOJOWO[NIO
-enbe‘(Js]pue
ISLoY]se93]q1ODpure[fomsv“Ayye“‘qIdp‘TND
-I9]BTIGSOAIOUso]A003ne]ouDATIESONIATsusonpqeumouyun“(Jp/SWISQ)s[SAoT-BS9UYO[ourd
pur[erryadAignsOAgsoon[sTeuouTeataAroyerdsay(Uy£0uoneyiqeyolyuo(sapokoou}JOTOUTTeuoxepuesur‘(Tp/su6p)UTS}WE]pure93]joyunod91400ydur4]
-edutl0}posieyosicyVN¢)osueyoxePUISeTg-douRYyUo‘uleIg=-JeUTTOAWOppoxT|Y~—_-od_[eJ0)pasvaroUyASHwindagaynjosqe)eruodoyduiATLO18909+WOd-LY[Sz]‘Te39suryoInA,
(poolq
WO}JOJSURTDATS
-sedIostsoyyuds
pourutzajopapiuounauddBIUONRIUDUIIPsjou)sorpoqnuepusvjdookysA00myAro“(7/9
Z-A02)-SUVS-HuepueaviuownaudOSZ-OOL:TewuOU)
CAID-SUVSJojSolpoqrue“(TP/SWO0F-O17ZSYIIMQJOEDATIBSOU‘¢8'QJOW3]puesnit,,:[euLIOU)Tp/suOSdjoyyueoyTusisolesasoon[sASOTenAouksAro}[eAd|USsOUTIGYjnouIAAjTTIGoULUOTB[NUSAJATSBAUL/umnas*WIU/sT[I9-pridsayy‘g/V“(7p/sut$-‘0-0'0
JoATQAOOAIYTTeoruryooul+(satoAossulpuyddiv=Z:Juno09[99“(IpSNIIABZUONYUt:jeuliou)“Tp/sur¢°Z(QUI0d-14SooIOJOTOSNUTp)adueyoxaTeorsoroujedsurzeds[eins/8W79)ulajoid‘AGA‘AIND10}dud‘(1/90'01-0'7oalesoupayeodar)
joyuouraaordwyJUONeurseid+30¢OTAIou:yeutdg=yimSuTeuTpoAWacy[e101posvoroUyWOdsanesonN=-|JRUOU)T/NT8OUMASOTOIIS+L.DIS9UD[rz]‘Te19JoqTaH
adAiqns
orsoyorsAydonsasneoSqH6I-CIAOODsqo-9919SHpureodAyWOUNDSOUL(jeurdsAuyedomaoyy:A8oJo}SuTUseTOspur
sUIODINOAdvroy]pueyuowseuryy=pureUTeIq)[YIN-jorsAydonoo,yssulpuy4SOsorpoqnur-onyssulpuypoolg_sTsouseIP6|-GIAOOpny
(penunuos)1aqeL

1157
1133-1170
Journal of Neurology (2021) 268
(skepfT
AWO
puspjdood“Fy
‘unfal
4ajo0qo}]
-Aduiv‘stds
14aflopsing
DIaL4OgUO$182}
Joye)asIeyosIpssulpuyddivOIBOTOIIS‘Sorou}yesuo}dudsTeorsofoujedSsuTyeUlpoAUOpsurajoid[euou-poqnurqIOH
P[TWJos0uajsTsI3gQUON(skep¢)39/8ZOIATou:uleIgAueurmoparg—“JUNOD[[90[RULION,-TWURDATIVSON,VN=Adojoros+YO[8994[87]Te10OUTIL]
€POO
“‘LOMH“A677
SNLITARUOIOZ
sSNITAOIg}Ua
‘SNITAOUIYA“snd
-Taoummoudeyour
‘SLITAOUSpe*ET
puevysodAy
snataTeyAouds
Aroyertdsartp
pur‘¢‘7‘]sodAy
SnIIAezuong
-urered‘oseouly
URIS
9}JO
(6¢'0-00°0)
LNSHeddignsSWZLS[PA9|$100]dATOUSUIpPN[OULCHJOWIC]-dpoyeasyo
yuowoAordutou}JOTOUTsodAjqnsSnJtATu/su¢°78UNLOFTeorsororsAydon-s0uryus:[eurdsGyVezuongutrumaas*(S'0-0'0-O9T9pueTROTUITSoummborssulpuy/8WLOT¢)UtojoIrd‘sosmIlAgqpue[eWOU)Tp/su$9
WIMskepCTJaye-o[yoAxorpAy“uroAUrTeorsoroujedddiv[e10}pasearoUrVezZUONgUr:10Fdad‘OLX96¢€LO1soyo+Ael-X
oWOYO]OSIeYOSIq«=-OIUIZe‘TouIeJOORIEY(skep7)89/8|OIATou:uleIgsuyeurpAWog=“WISJUNO[JaSuTtEOIOSOATIESONOd‘01X9'SOAM1soyo+YOd-1LY[LZ]Te10BCU
SYIOM7
Joyessouyeamsepp]IO}IIAssulpuyumouyunstsoyAo0q[d
oposnurJoWSU-PuoI/MAeUTdoTpurTeorsofoujedadAiqnsOIAou‘(‘7p/supp)[97]-OAOIdUTTRUNTUTYAy«=:ouTNboroTyoAxorpAHuojostupold[RIOou:UIeIg=xoHal-yUT[GJosqy=UTajoAd[v10][PUTIONVNVNWOd-LYTe19ouvureryove
adAiqns
orsoyorsAydonsasneoSqH6I-CIAOODsqo-9919SHpureodAyWOUNDSOUL(jeurdsAuyedomaoyy:A8oJo}SuTUseTOspur
sUIODINOAdvroy]pueyuowseuryy=pureUTeIq)[YIN-jorsAydonoo,yssulpuy4SOsorpoqnur-onyssulpuypoolg_sTsouseIP6|-GIAOOpny
(penunuos)1aqeL
pringer
QS

1133-1170
Journal of Neurology (2021) 268
1158
Bisayjsovsed[eIsIpyuoursouRYyuS
pureutedormjedorzJOOIdAIOUWd-NOUJOVOUIISISIOg[erIoesoquinyT-AOD-SUVS
“QOUBISISSEUJIM:paooyeuidsddivy2%anesou“qrysTpa0<UMU/STI29OOO'TTEyes0}AjIgessulpuyuzoyed$JUNOD[[99“(TpDd‘luwysT[II0009purstsorrdenoy(skep¢)Teorsoroujedsurzeds[eins/8WQP)utojordsoydooydurdgy*wut
joyuowsaoidwyUI[[LOrXOoUy3y/8UOOFOIAIouTUIRIg=YJIMSuTJeUTTaAWIOC][e}0}posvorouyVN/STI9°9OOOPOAM=ABI-K1899+WOd-LA[1¢]Te39ouvose’T
BisoyjsovredddivApueurmoparg
[BISIPpuevrxoporeusoyedSureds[eins<UMUI/ST[2°000'6TTTTjoo0ualstsiogUiTeuoxepueTWysTI90Z:JUNODDd‘WU/STI99008“AIDAOOSIJOIOULuroAU(skep¢)(syporqUOTIONpUOD)119°“(Ip/#wOr)soydooydurdgy*wut
TTDyYIM[BsstuUsiq]§-o1YWTe]O“UTTTLOLXoury33/800hOIAIVNSuneuradwappext]uroqordye10][PWONVN/STI2°DOSEDAMAAI-XIS949+YOd-LA[T¢]Te9ourose’T
wd
CAID-SUVS
dnpurjs0]91qVUOTILNUIASATSPAUTumruljopes¢:sayA000ngT‘(Tpsapoqnue—QOS‘SPOd+,wuUI/sTTI9Ayantsod93])WSs]
“stsomede.yoyTeorueyoour+(sAep¢)JOOISAIOUddiv/8W99)urlajoidoprisorsuesOOZIsadooydurfToaryisod+Avi-X
joyuowsaoidwyULDAWIOIUIZY3y/8UOOFOIAIou:yeutdsSuneurpoAWog[e}0}posvorouy“Tursanesany—*WIU/ST[990068OAM.soy+WOd-LY[1¢]Te39ouvose’T
II]2Ar0u
[etues1ooT
ou}JOTRUSTS
osuaqurradAy
GL
pue
winrar]
-OpesUIA
yuowrsouRyUS
skeppyuouttmoidosuelJoljeas1eYOsIpJUOULTeooatnbaou}Ur
quowsaoidwy=sumboropyoAxorpAHyOIA=-a8re[UosurergVNVNsotpoquue[JADVNWod-LA[og]‘Te39soyue’T
skepZIr9ye
OSsIYOSIp*Xaor
sdao1q1J9T1O0ysnitaTenAoudsjdooxaeIxoporeAxoyerdsorpoeztyersuesjo(qWnysTI20Z)pureezuongutgoua}sisiodYIMyunod[[99[euLIoUDATIESOUSSOIPOG
swojdwidsSq(shep¢)ddiv=‘(7p/8urgg)uray-Jueeprsor[surs(Tp/sw76’1)(AeI-XIsaYyo
joyuouraaordwyJUONS3y/BUlOOFOTAIWNsuyeurpoAmiaq]=-od[#0]posvarTOUyT-TWURDANVSONH§=qYOpasvorourAPYsTSOANIVSOU)YOd-LY[6z]Te19odweT
adAiqns
orsoyorsAydonsasneoSqH6I-CIAOODsqo-9919SHpureodAyWOUNDSOUL(jeurdsAuyedomaoyy:A8oJo}SuTUseTOspur
sUIODINOAdvroy]pueyuowseuryy=pureUTeIq)[YIN-jorsAydonoo,yssulpuy4SOsorpoqnur-onyssulpuypoolg_sTsouseIP6|-GIAOOpny
(penunuos)1aqeL
pringer
QS

1159
1133-1170
Journal of Neurology (2021) 268
pringer
QS
umouyun
adAignsOAsep¢JoySUIQOTeuoxepuesur
AreuonesQuUOTOSTUpsIdAMIOJYQuUOTOSTUpsIdATIOPyVN=-JeulpoAuappoxTpyWNWNWNWOd-LY[€¢]Te19moursueypy
SoproOsIp
JUNUIWTOINGOFWd$]S9}[BOISO[OIOs
CAID-SUVS240eanesouADHddiv~PBSOU*WUUU/[[99¢‘AGH‘ATH240)
“TTAVUOTTI{TARUICOT(skep¢)Teorsoroujedsuryeu/swZL)wiajoidoptsorpsues
yuowsorduy=‘outnboro,yoAxorpAHAep/sx/3uOOrOTAou:uleIg-yaAurapATUTeAT[e101posvoroUy-TWURDATIVSON,WNWOd-LY[€¢]Te19moursueypy
OUNWIUITOINGIO}Tu/sdQ'OT20-4NL
$189][BOISOTOIES‘(qqui/sd791-19)
Teoruvyooul+SUOTumouyunodAjqns-SUVSoanesou‘AGH‘AIH9411“(Tuy/sd°9-8'0)-ostupordyAyjourssulpuyOWATeuoxe‘WwUy/[T99[:sayho-edou‘sorpoqnueTu/sd9°6:9-T]suo}dutAs10j0UL“TTAVUOTTI{TARUICOT(skep¢)Teorsoroujedpuesuneura-oong]*(Tp/sulOr)optsorpsues“(qu/3d100'0>)
joyuouaaoidwmy=‘autnbozo;yoAxompAHAep/sx/3uOOrOTAou:uleIg-AWOPPox,urajoid[v10][PUTION-TWURDATIVSON,qu/sd9:1-TIWOd-LY[€¢]Te19moursueypy
OUNWIUITOINGIO}Tu/sdQ'9OT20-4NLUOTB[NUSAJATSBAULWd$]S9}[BOISO[OIOs“(quy/sd791-19)TeoruByoowl+qeunZCAID-SUVS240eanesouADH[wysd0°07:8-Tl
suo}dutAs10j0UL-nJep“ITATUIRI[ISO(skep¢)ddiv/swZS)urajoidoptsorpsues“(qu/3d[000>)
SOSTLILA
onsuogpue
SnilAgasourder
‘SOSTLILAOIOJUF]
‘sasndiasodiopysorpoqiue
‘SISOJMIAIGHIWNLLAOH-nue‘AgdH
(%S6)-ajonqookyy“Tung-Hue‘AJH-HueTToutJeerxogyaoddnsuasAxo‘eliajoRqIO}YOduindossATIeSOU-o10dAYJOUTUNIOF‘AdevioyyONOrquuessulpuyHSOsanesou‘(7psorpoquuejdaoxosumojduAs‘gutnboroyoAxorpAy(skep¢)Teorsofoujed/8WI67)UtojoIdoptsorsues
TleJoUonNTosoy“TABUOTLA/ALARUIO'T3y/8UOOFOIAIou:UleIgVN[B10}]pasvarouy-WUBSATIESONVNLOsuo+MOd-LN[Te]Te9Mouesueypy
adAiqns
orsoyorsAydonsasneoSqH6I-CIAOODsqo-9919SHpureodAyWOUNDSOUL(jeurdsAuyedomaoyy:A8oJo}SuTUseTOspur
sUIODING
Advroy]pueyuowseuryy=pureUTeIq)[YIN
-jorsAydonoo,y
solpoqiur-oiny
(penunuos)1aqeL

1133-1170
Journal of Neurology (2021) 268
1160
preyesSurber
NOYRIXEIe
WSISJo9ouUaIsIS
-Jog“UOTRUTUIeX9
yespurJojour
joyuouraaordwy
skep¢
JO}pigSWOPQUOTOS
-TupordyAyyour‘ourz
‘gutnboropyoAxorpAH
sjooroutnbo
Bpnedoy}Jo
yuoursouRYyuS
qoours:ourd¢
(sUOTSsos¢)osueyoxePUISR[g
ddiv
SuTyeUTPOAWIOC]
XOpUTN38]pue
spueq[euo[s08I[O
oanesou‘tourd
snieydsousysiis
-UTUDUTSATIRSOU
WOd-LY7-APD
“SUVSASO
oATIeSOU‘CUIW/Z
:JUNODS][99[2101
‘(Tp/sut€1z)wt91
-old[B10]posvoroU]
(poytoads
JoyJINJJOU)ssoon{s
puejunoo[[90[PUL
uoTyEnead
onsetdosuried
DATIESOU
“UOTIOIJUT
OWIYIMJUS
-JstsuooASOTOIAS
AWDpueAda
‘SUIJSO]
OSBASIP
OUIA'T‘SNITAOTIN
soa‘sTpTydAs
‘AJH2anesou
solpoqijueoprsor[s
-ued-T]URDATIESON
(1/0€L)
OSBIOJSUBIJOUTUIPouru
-P[e“(U/W9Z)ASA
“(T/Soul
CLG)
UNLLEy
‘(Tui/su
069)
Jounp-a
paleasta“UNOSpoo[q
poroydwios[ewI0oN
dap
pue
(AOd-Laoanesou)
LO1sayo+wa]pue
(3'0>[euzoU7g
IONTLAXOPUL)HS]
CAID-SUVS
SANISOd
[9¢]
‘Te
19
Jeppen
yUOWIOAOIAUIT[BdTIARUOTT/ALABUTCOT(skep¢)ddIv—_Jou‘(7p/su6g)USTpaeagso‘ered[s¢]-TUITOJUROMIUSISONN=‘auINboroTYDAxompAHAep/syx/sutO0rOTAWNSuTeUTPOAWIAC]Uld}OId[e}0]posvaIOUyVN-oydurAqT‘stsol£o00neTLOSUI+YOd-LYTe19Yeuediyapyzoypw
(peygtoadsroyyang
Jou)asoon[spue
-jear]SuTIeIsWOTTIARUOTT/ALABUTCOT(skep¢)NVSWYV“(qp/sui7S)urayUSTpaeagyo‘evruad[s¢]skep¢Jayeyeaq,«=‘outnbosoTyoAxorpAHAep/sx/3utO0rOIAWNTeuoxy—_-od[e101posvoroUyVN-oydut¢q]stsol£o00neTLOSUI+YOd-LYTe19Yeuediyapyzoypw
BrxoqorodAy
jod0uajstsiad
‘AJoaooalayo[dwio)WNAep/sx/3w0OpDIALWNWN-HojorMoourumnqryWNdad‘OPATULIONUOd-LA[e198yeuedryapyzop
oanqynssisored[eroryiqpureulejswerdPwJoa0ua}sTspureA8oforssASH-Iod‘syoom¢HSOsanesouJolessouyRoM‘yUNOO[[90TeWIOU
SPOSNULJOJUOUL(sapokoddiv=‘(Tp/su61)urayUSApueCLOAsay[se]-QAOICUITJUBOYTUSTSWN¢)aduvyoxoeuse[gWNsuyeurpoAmiaq]=-od[#0]posvarTOUyTWNdOOAM[PULIONOANVSOU)YOd-LYTe19Yeuedryopyzoyw
UOTRAZTAIOWIG-d[re]sdepQ|JoyeyleodVNVNVNVNVNVN‘eruadoyAooquioly|,LOweyot+yod-LaTe19BIMsuq-ruyL
(qwysdg'¢-8"1)
oy:O1-T“(rm
/3d
O'S€r1-0'0rP)UOTB[NUSAJATSBAULqw/sdOo€O7ZI-AZ-TTeoruvyooul+uTTOSoproOsIp“(quysd7°Z1-8"L)Tw-KOAXOp‘O[OZOUNWIUITOINGIO}/8dTLL:©-ANL-euoony“UTOAUTWOd$189][BOISOTOIES‘(qqui/sd791-19)
WoUsdoIOUr‘oUOTumouyun-e30u*UIUT/[[99Z‘AGH‘AIH940“(Tuy/sd°9-8'0)-ostupordyAyjouradAignsOA:saqAooong]‘(Tp-e3oU‘sorpoqnuequysd/°7¢:9-T]“TTAVUOTTI{TARUICOT(skep¢)Teuoxepuesur/sw¢¢)ulajoidoptsorsues“(qu/3d100'0>)
yuowsorduy=‘outnboro,yoAxorpAHAep/sx/3uOOrOTAVN=-JeuIToOAUIOppoxTp[[e101posvoroUy-TWURDATIVSON,qwy3d70:1-TIWOd-LY[€¢]Te19moursueypy
adAiqns
orsoyorsAydonsasneoSqH6I-CIAOODsqo-9919SHpureodAyWOUNDSOUL(jeurdsAuyedomaoyy:A8oJo}SuTUseTOspur
sUIODINOAdvroy]pueyuowseuryy=pureUTeIq)[YIN-jorsAydonoo,yssulpuy4SOsorpoqnur-onyssulpuypoolg_sTsouseIP6|-GIAOOpny
(penunuos)1aqeL
od
v
50
|
‘S
a
Nn
ll

1161
1133-1170
Journal of Neurology (2021) 268
uone[nuca
sutinbarpue
(Tr-TT
TOW)$"¢
asoonty“(¢-0)TH
Teonto[TMs‘uonssulpuy/ST[9°ZT:saqAooong](LO1s9y9-esTjeyidsoyjouoTe[UGATeorsofoujedddiv(T/89'9)ureduosouLiqyyTeulou)(poytoods
(Sutosuo)skepOFDATSBAUT[ROTURTYPOJATOTAou:uleIgsuyeurpoAmioq,§=-0ud_[#10]posvarToUyTVNpureqyYOpeseoiouy+40)sisouseIpsuo[Or]Te19UosIa}Eg
suruund
PomTenueul
joo[qedeouryng
(aoedsuadoue
ssoroe)UI¢eA“(S-g)TH
0]91qeO8IeYOSIpP/STI99€:saqAoOoNIT(LO1s9y9qe‘uonestendUONLINUASATSBAUTddiv“(T/8SQ)ula1duopueyeuliou)(poytoods
-soyJoskvp/TQuONTeoruvyooul+OTATVNsuyeurpoAmiaq]=-od[#0]posvarTOUyTVNsttydormnoupaseaiouyjou)stsouseiparuyac][or]‘Te19UosIOIVg
powojiedjou
sorpoqnur-oyne
‘14afs40psing
DIALOG
‘T-AIH‘Ada
‘AZA‘ASH
‘apruounaud
sn220901dAAs
‘ppydounaud
-[TUSASATSBAUTTVo01XT‘AWD‘vluJOWIp-d[BULTeoruvyoourUTMUOTB[NUSAJATSBAULNVSIV:JUNOD[99‘(IP-oumnaudJou“(T/,0TXST'8NO]‘uotssnupeTeoruvyoour+(skep¢)[euoxe/8Wgy)ulajoidpuispjdorkyIO}sttydomnou)
wo9kepryVN33/8WOOFDIALVNAlosues1OJ0J][R10]peseaiou]SurusaiossanesoNT,O1XIv0TOUMLO1899+YOd-La[6¢]Te39tuorpeg
ddivTH/stI99
oInreyURSIOApueurmopsarg9):JUN0d[]99‘(TpsorpoqnueYOpueqyo
-UOSIOMSAISSAISOIGTABUOTLI/IIARUIO'TB8yx/3UOOFOIAIVN-yaAurapATUTeAT[e101posvoroUuy-TWURDATIVSON,‘eruodoydurs'TLO18909+WOd-LY[g¢]Te19UeIAReNO
soouonbas
UILS
Ul
sosn
-xod
requint
pure[eTorsq
ou)surAqtddns
$]OO1OTUOT[S
-ue3-jsodJo
AyisuoquriodAy
QOUvISISSEINOUJIApuesurusypryy
eM0}BIQRSBAKTeormourmAseddiv(LL'61)oYspuresyoom7(AepJoyo:outdspuruzayyedsoyAo00ng]OUasequsorad3]A00u0UL
JoyequowaAO01dUITUlOAWIOIIZEAIADUO‘SUOTSSasrequintsutzeds[emsUIA(Tp/sur9°77)Ysty&pue(qry/sT[90LO38949+LAIN[L¢]Teorsofomnoupoysepy=‘ouTnboroTyoAxKoIpAHOAL)BSULYOXSPUISP[pure[eoralad«=YMSuTJeUTPOAMIAG]«=UTa}OId[e10][PUTIONN«=:SATIVSOUISO]ATH=Gh"].)PTUOdonoUPITA1soyo+YOd-1LYTe19nsIVyY-ZznsO
adAiqns
orsoyorsAydonsasneoSqH6I-CIAOODsqo-9919SHpureodAyWOUNDSOUL
sUIODING
Advioy]pueyuowaseuryyy
(jeurds
Ayyedomoy:A30
-jorsAydonoo,y
JoySuIUSETOSpur
solpoqiur-oiny
stsouseIp61-CIAODopr
(penunuos)1aqeL
pringer
QS

1133-1170
Journal of Neurology (2021) 268
1162
Ayyedo[norperuot]JoAyyedo[aAut
-ByTIqeyar7AepJOQ0UNpPTAdOUddivuo‘USWAOTdUUTUlOAMIOIYIzepur(skep¢):outdsrequintsutzeds[ems
Aroyertdsal+Aepudoumnboro[yoAxorpkHLSy/BUlOOPOIAIpuro1tovioyu,==yasSuyeurpaAuocyWNWNWNWOd-LA[cr]‘TeJoBURY
poyoaye
Ajpenboo10M
$]O01SAIOU
JoLajsod
purJory
“euinboepnesyuNOod[[99[eULIOUuonelyou)SuIpnyour‘(78wE701)-U9A[ROTURYOOULauidsoyJourajoad[e}0}popeouT[HsIngS[PAQT[Te1BposearourstsoredTesso[s$10019AIOUme,Aepry-oddypur[etaryasueyoxayeurdsay]JoWOdT-APDJOUOTSSOIZOIYIMpuiseyd+uore[UGAyuoursouRyuS-SUVSdAnesou
yuowrsaordtuitDATSBAUL[BOyseUOS‘qri/6:JUNOO[[90solpoquurJOJOUL:UOTSSTUIpe-Tueyoout+(skepS)TeotmoumAsddivy=‘wiajoad[e10}[eusoptsorsues
wo[¢AeplyVNBOCOIA]aatsseur:yeurdsSuneurpoAWiog]+=-JON:UOISSTUIpeTW-TUBSATIESONVNLoOseo+yod-Le[7+]Te19woyoyayg
SquITT
[PISTp
ULUOTJBSUasYONO}
JYSITposvaroopOOMBIO}pureerxoporodAyAepJadsouit]omy
pozijerouosBUYYZeydinsUOTIVIOOSSIP[RO
Josouajsisiag—suINboOTYOAXOIpAH(shep¢)307DIAIVNVN—8ojo1fo0urtungpyWNVNWOod-La[Lr]Te39seqkeg
‘TOTRIEQET
UJIMpopfomuo0s
AqqngssaoonsAjIA
-OBOI-IIAOOT1JOU}
-edwids‘stsoredoangyns[BIORJTeAOIeIIGpurulejsWeisPru‘squiy[eiIsTpAVIATIOBAI-IOAOW9]sAsoatyesou‘ASOTOIISULUOTJBSUasYONO}snoasouonoyyedurAs[RITASO[TewouJYSITposvaroopOOMBIO}[OIJUOD0}[OTRIOgRTumouyun‘yUNOO[90pue‘erxaouodAyAepJadsouit]omyjosnjogsnousAeqUtadAiqnsOIAgsoon[sTeuoupozijeroues3UQOOZaeydins‘gsueyoxoeulse[dTeuoxepuesur“(Tp/sur6¢[)UIAd
josouajsisiag=sutnbosoryoAxorpAY=otnadesay)Josuorssas¢VN~~--JeuTjaAtoppoxt—s-0d[B10]posBarOUyTVNVNWod-LA[Iv]Te39seqdeg
surTuunI/yIom
[enueutjoa[qedHTT-BOUTInq(aoeds¢yjoumul)£°¢uadouessoror)gsoonTy‘(S-0)TH
UWYB0}9IGRssulpuy/ST[99|>:saqho00ngT(LD3say9‘uonestreidsoyTeorsofoujedddiv(1/860)UIA1yeuliou)(poytoods
jo(Sulosu0)skep1WNOIAIou:uleIgsuyeurpoAmiaq]=-od[#0]posvarTOUyTVNSSUIpuyyUROYTUsIsIONJOU)sIsouseIpsTUyOC][Or]‘Te39UOsINIEg
adAiqns
orsoyorsAydonsasneoSqH6I-CIAOODsqo-9919SHpureodAyWOUNDSOUL(jeurdsAuyedomaoyy:A8oJo}SuTUseTOspur
sUIODING
Advroy]pueyuowseuryy=pureUTeIq)[YIN
-jorsAydonoo,y
solpoqiur-oiny
stsouseIp
61-CIAOD
opr
(penunuos)1aqeL
pringer
QS

1163
1133-1170
Journal of Neurology (2021) 268
omnpreyA104
-vidsalsATSsorsssulpuy
-oidJoasnvooqTeorsofoujedddiv
sskep/Joyeyyeoc]VNVNou-urelgsuneureduoc]9UONVNVNLO1899+YOd-La[or]‘Te19SIpts
suo
-BIUIOYOSIP
[eIqovI9AIO}UT
[TBOLAIO9daopueom]:Teurds(SprOLsodooydurs]
“TTAVUOTTI{TARUICOT(skep¢)Teorsoroujed[euoxynau)OTX91
povlodarjoN=‘outnbororyoAxorpAHB8yx/3UOOFOIAIou:uleIgAJosuasJOIO|VNVNOAMposeorouyLO1899+WOd-LY[S¢]Te19weYysepss
VONV
-d'VONW-9
“VNC-Hue
“VNVoanesoussurpuy[eoUOTIVIOOSSIP[RO‘ASO[OIOSVITOI-Isojoyjedou-I80[0]A00uTUINGe-Iogpurerunfor
AIQA00aIBJoTduI07JUONSy/3UlOOFOTAIVN‘ureigSsuTeUrpOAWIOC][e101posvoroUyDATIVBON-puy[eorsoroujedoNWOd-LA[Ly]Te39[preyos
yuowrsouRyUS
TeosuruoulsayA000ng]
"SSOUBOM[TROLAII0pure€:JUNOD[[90solpoquur
JoJOsSUOOU}JoIEUlOAWIOIIIZE(skep¢)wroysuTeIgddiv‘(1/898'0)wrajoidoptsorpsuesARY-K[or]LAep&qSutroaoooy=‘aumbor0TyoAxorpAHSy/3UlOOFOTAIrouTdsSTOULAA,SuTyeUTPOAWIOC][e101posvoroUy-TWURDATIVSON,WNsopo+YOd-LYTe19Buepres-oyours
AIH‘C-T
ASH‘AZA‘AWD
ssulpuy‘AGA‘ZAIN
[eorsojouredddiv“SUVSJOJWOdsorpoqnur
AepWIOTWu}JoIe(skep¢)ou:yeurdssutzeds[emsATIVSOU‘sT[I0puroptsorpsuesssur(MOd-LY2aresou)
quowoaorduitA[MoTSJUONSy/3UlOOFOTAIVNcureIg=mSuyeurTpoAMag]=uTajold[v10][PUTION-TWURDATIVSON,-puy[eorsoroujedoNASOTOIIS+L.DIS9UD[Sr]‘Te19BATY
ddiv
uonelyiqeyaryuu[eorsoromouyuonb-QATOAUTWo}suTeIq
-9suor)‘uredpurpue[eutrxoidqtUOTJBIOOSSIPvidordip‘stsomdAuyyedomouopnorpTeorsoroyAoourut
joyuowsaorduit-INJ“Xopoy-Uy,:JUNOD[99‘(IPsorpoqiue
WTou)J9TVWNS3y/BUlOOFOTAIVNWIMSuneurpeAuog[e101posvoroUy-TWURDATIVSON,WNoatyesou)ASOTOINS‘Te12OusNg-sosdy
adAiqns
orsoyorsAydonsasneoSqH6I-CIAOODsqo-9919SHpureodAyWOUNDSOUL(jeurdsAuyedomaoyy:A8oJo}SuTUseTOspur
sUIODINOAdvroy]pueyuowseuryy=pureUTeIq)[YIN-jorsAydonoo,yssulpuy4SOsorpoqnur-onyssulpuypoolg_sTsouseIP6|-GIAOOpny
(penunuos)1aqeL
pringer
QS

1133-1170
Journal of Neurology (2021) 268
1164
yeoutso
IIHS7Y90wTW
“eIsoidenoyS]OOIdATOU
AroyertdsarUONLTNUASATSBAUT-20uryuo:[eurdsATIVSOU‘STIIOBLINUOLOY0]onpTeoruvyoowl+(sopoAO=:SSUIPUY[VOIsOTNVIANVou‘([p/sut¢6T)sorpoqnueroprsoACT‘duopasvoroutr
UOTSSTUIpeFDIULOIWIOIAZYZ)Sx/8WOOFOIAT=-ouredou:urergTeuoxeIOJOPYUrsjoId[eIO]posvorOU]-1[sus-TULSATIRBON‘erusdoyAo0ydurah’LO18949+WOd-LY[ZS]Te19ouRosol,
SSOUYBOMssulpuyqeroryjoTeorsofoujed
yuowoAordutou:yeurdsWOdT-APD-
BIXe]eJoSAIOU[RIOR]JONVSIV‘sT[90HaT
yuowoAordutyuowoouryussurseds[eisYIMou‘([p/sut¢ZT)GUO‘UNLIEJposvorour(LO1s9y9
$JIMIVUlT[OAXOULYS3y/BUlOOFOTAITuIeIg[euoxeAJOSUDSIOJOJUTAJOId[eIO]posvoIOU]WN‘erusdoyAo0ydurah’OANIVSOU)YOd-LY[ZS]Te19ouRosol,
OdC-AVD-SAVS
SATESOU*LULU/p
UNOS[99‘Tp/sur
(LOL)uteioid[e10)visotdered$]OO1dAIOUposearour:gyAeqTTpur‘erseydsApUONLNUASAISBAUT—s-TepNedJoJUOUTWOdT-A0VD
‘ssouyeoMTY)-uou[eoTuRyoou=-o0uRYU:yeuldsNVSIV-SUVSoanesouBLINUOLOY
o719Aa8JO909}Arerodura}+(sopoho.—SBUIPUYy[ROTsOTsurieds‘sq[90ou‘utojoI1dsorpoqnueroprsoACT‘duopasvoroutrASo[OINS+LD
-stsiad+yoomTYJoulvjoovlegZ)8y/8WOOFDIAT=-ouedou:urergTermsYIMTeuOxY—-[eI0}[euMTOU:7Aeq-1[sues-TUeSATRSON‘etuadoyAooydurh’'Tsoy+WOd-LY[ZS]Te19ouRosol,
uoTeIIqeyoio1“uonouny-nouJayesyeomTeuarpueumntssejodILpaistsseun‘UINIpOS‘OIMASZITIQOULOF91Gu[BWION“(T/S8tUOZ)‘ssouyvomSqUITTduporeasyaJOMOTpueJoddnVo0LXLunoo[[99ATpytug‘(qyourur¢°¢)poaoidut‘ersotdip(skep¢)dqdiv§‘(1/8S71<)ursedpoo[gSNOudA
[eroryJouoNNTOsOYyQuONAep/sx/3uOOrOTAVNsuyeurpoAmioq,§=-0ud_[#10]posvarToUyTVNUO94R1ORTPoeAs[yWOd-LA[1S]Te19ILL
VONV
pureIesponuue
auuBYSWINTOTeO
poies-o3R][0A
Jojdo001SUIT
-OYoTAIo08‘SOT
SSOUWBOMT°T:OGM—pueqrdD‘TINDoT9A98JO9009}(skep¢dadiv‘(7p/sw¢[¢)urayoptsorsues
-stsiadgzAepuOJUONJo})SyY/WIBZOIAWNsuyeurpoAmiaq]=-od[#0]posvarTOUyT-TWURDATIVSON,TysTI9°NOOOSTLOAM=ARI-K1899+YWOd-LU[os]Teyens
adAiqns
orsoyorsAydonsasneoSqH6I-CIAOODsqo-9919SHpureodAyWOUNDSOUL(jeurdsAuyedomaoyy:A8oJo}SuTUseTOspur
sUIODINOAdvroy]pueyuowseuryy=pureUTeIq)[YIN-jorsAydonoo,yssulpuy4SOsorpoqnur-onyssulpuypoolg_sTsouseIP6|-GIAOOpny
(penunuos)1aqeL
pringer
QS

1165
Journal of Neurology (2021) 268:1133-1170
[99]BaioonsouseIpuoIYysiig0)SUIpPIOIDV,
yasuoswmojdudsSqnWIMJuRITWWOS-UODPdJIpPISUODsemIIpeUpoyJodassemUOIssosO0IdOUUSYMsINJoId[BOTUT[DJSIOMOY}JOJUsWUdO[IASpoy)puswWO}dUIAS[RdISO[OINOUJOJOSUOBY)UdEMI0qposdeyaskep0}SIOJOIIIPEN0}OWL,Aydersorpes:ABI-xX{S][99POOTGSIUMSOA{SNITA1d]SOZ-BITOOTIVA‘AZASAIOTIOGR’TYoIVasayasvasIgl[RIOUSA“TYCA‘squiyJeddn“JQ‘101-OBJSISOIDOUJOWINI“NLLfZ-SMITABUOIOSoWOoIpUASAIOyeIIdsalOINIDEBIOAVS‘T-AOD-SUVS‘UoMvayuleYyDssesrouATOY“WO‘unosjopaieTd‘Dg‘opquyrTeavjou‘YN‘SuIseUNsouRUOSALoTOUSseUTTMIA{97euw‘WW‘squalyJamoy“TTSaseuasorpAyapo1e10P]‘AQ’SULyNepI01UI“TY{sul[Ngo[SOUNTUUITSNOUdARNUI‘OTASULyNpIOIUT“T]{UNs1Vd-dATSUSTUT‘Oy‘snaxopduntsxadsoy‘ASH‘sndtaAouSTOyYSpouNuTUTTURUINY‘ATH‘UIgo[sousey‘qH‘oseuTwesueyoyeantAdayeurein{s‘gd‘oseunuesueyoNSovOTeXOSTUULINIS‘LOD‘osesaysuen[AUIeN[s-vUIES‘THD‘owmorpudsgazeg—ureyqiny‘SqyQ‘orem‘4fojeluoNeWoUTIpesaAd0INIAIO“YS{sndqtAIeg—utaisdq‘Agg”‘smiypowsajeqeip‘Wa‘Aydeisou0)poinduros‘{7‘ping[eutdsoigaqes‘4S7‘ulajoidsaTovel-Z‘dD‘6107QSLISIPSNITARUOION‘6T-CIAQD‘aseasipAreuour[ndsanonIIsgoIUOIYO‘GdOD‘snsTaopesauroyAd‘AJAD{asVUrysUTIBAID“YD‘osvav]IepooaTvoyouoIq“Tyq‘serpoqnueotwusedoyAd[rydomnou-WUe“YVONYV‘selpoqnuemesponunue‘yNyV‘Ayiedoinou[euoxeArosuasJoJOW9yNde‘NVSIY‘Aqyedoinou[euoxeJojowonde‘NVINY‘AyiedoinoudjodsuneuradtopAIo}VUIWUeUToyn5e“GqlV
sumojdurAs
AroyerdsarpurToLX¢Juno
uonnjosarg¢Sepry/ltaeutdoy‘TopiqryjouSUISOp)DIATVNsuneureduac]Urajoid[R10]pasearou]VNOd+01X770OPMLO1899+YOd-La[9c]Te9ovyZ,
2snnedoypueUd[RIAcanesou€sanedoy‘ATH
‘WdZ-APD-SUVS—-ABoyouasstprydAs(7/8$z)duouoT]eTQUAUOT]eTHUSAdaTesou‘UNOS‘soipoqnuepeste(T/,OTX064)pureyuowomnberOATSBAUL[190puessoon[soprisorsuesstsoyAdoquiomyy
uaskx0OUSDI[eorueyooya[+(sAep¢)ddiv[ewiou(7/81¢°0)“Hue“VONV“CT/,01X6'0)LOas9yo+Avex
ULya0mM|INVAB[OTXOUIR-07)Aep/sx/3uOOrOTAWNSuTeUTpoAWIAc]UldjOId[e}0]posvarIoU]“VNVdATesoNviuadoydurh’'Tysayo+YOd-LY[SS]Te19qqony,
AqpIowy
uoTeITTIGeyalBOF
JUG“ssouyRoM
TTjos0uaystsiod
‘sumojduAsTi)Josasop
UOTIN[OSII“UOTLTQIOJPlqSUINOT(skep7)ssulpuyTuY/suST'O7uTUOy-TU9A[BOTURYOOULuoy]}‘sasop7ISIgUOTB[NUSAJATSBAULTeorsoroujed~Topeoord©]X117
‘DIALJOpAepry—-esummboso[yokxospAH33/8WOOFDIALVN‘ureigWNWNWN“01X9°8OFMqusoy+Jod-11[ps]Te39Tue
AdvioyyuashxoMOG
-MO]+SPI019]s09
-100‘UT[[IOTXOUIR
WN=‘oumboso,yoXxorphH33/8WOOFDIALWNsuneureduoc]WNWNWNABIXISOYO+YOd-LATR18URTRDsokrjaa
AJB‘ezuengut
‘AZA‘ASH‘AWO
juapusdap-B[TUDAQATSBAUT[BO-SUVSaayesou==—s--2ango}XduinDoj(TVpueqemsuonepuaa‘erseyd-TuRyoou+osueyoxe=SSUIpUyy[RoIsoT‘UIWI/EJUNOS[20BuTUsarOsGATeSOUTessuAreydoseuut-skp‘eisopderayvusei[d+3y=-ouyedou:yeurdsddIvoy‘(7p/suOr)‘sorpoqiueroprsoHC‘dOposearourWOd-LYsaesou)
ploorypyoomTVJUON/8W00FDIALVN‘ureigsuyeurpoAWog]=urTajor1d[e10}[PUION-T[sues-TuRDANeSON,terusdoyfooydmAT=ASOTOINS+TDIs9yO[ZS]Te19ouRosol,
purisssUIpuy[RoIs0]|
0}o[qeunynq‘Tf)-oyredou:teurdgOdT-AVD-SAVSBLINUO}OY
UTJUSWOAOTCUUTssUIpuy[RoIs0]|ddivALSO‘STIIOuOposeosoutr(LO1s9yosaTesou)
PW+yoomTVJUONS/SOOPOIA=-oujedou-urergsuyeurpoAWagY«=ou‘uajoud[eULION,WN‘erusdoyAo0ydurah’ASOTOINS+YOd-LY[ZS]Te19ouRosol,
adAiqns
orsoyorsAydonsasneoSqH6I-CIAOODsqo-9919SHpureodAyWOUNDSOUL(jeurdsAuyedomaoyy:A8oJo}SuTUseTOspur
sUIODINOAdvroy]pueyuowseuryy=pureUTeIq)[YIN-jorsAydonoo,yssulpuy4SOsorpoqnur-onyssulpuypoolg_sTsouseIP6|-GIAOOpny
(penunuos)1aqeL
pringer
Q)§

1166
Journal of Neurology (2021) 268:1133-1170
the notion of a prominent post-infectious immune-mediated
mechanism. However, in this context, the massive release of
cytokines in COVID-19 may also contribute to the amplifi-
cation of the dysimmune process underlying GBS [76, 77].
In this regard, the increase of blood inflammatory markers
(e.g., CRP, IL-6, TNF-a, IL-1, etc.) in GBS tested cases may
reinforce the hypothesis of a systemic inflammatory storm
in COVID-19 [76, 77]. However, given the limited data, we
could not perform an accurate analysis of the distribution
and, eventually, prognostic value of inflammatory markers
in COVID-19-associated GBS. Moreover, we cannot exclude
that in cases with GBS developing before or together with
COVID-19 symptoms, the disease might have progressed
sub-clinically in the early phase to manifest afterwards with
its typical systemic clinical picture. Indeed, two cases [10,
12], who tested positive for SARS-CoV-2, never developed
COVID-19 respiratory or systemic symptoms and one of
them showed an asymptomatic pneumonia at chest-CT [12].
However, only more extensive epidemiological and transla-
tional studies, with the aim to compare the characteristics of
GBS associated or not with COVID-19, could clarify these
issues.
In our population, most common clinical manifestations
and distribution of clinical variants resemble those of clas-
sic GBS confirming the predominance of the sensorimotor
syndrome compared to MFS and other rare variants [57—59,
66]. Similarly, the results of CSF analysis reflected typical
neurochemical findings in non-COVID-19 GBS. In the lat-
ter, elevated CSF proteins and pleocytosis were described
in about 50-80% [57, 78] and 11-15% cases, respectively
[58, 79, 80], largely overlapping with the percentages in our
cohort. In this regard, the mostly normal cell count, together
with the absence of SARS-CoV-2 RNA in all tested CSF
samples [6—9, 12-14, 16, 21-24, 31, 33, 36, 42, 44, 52, 55],
makes the possibility of a direct invasion from SARS-CoV-2
into the nerve roots with intrathecal viral replication less
probable. However, a possible bias might rely on the lack
of systematic data concerning the latency between symp-
tom onset and CSF sampling in COVID-19 GBS cases. On
another issue, in a further case of MFS associated with-
COVID-19, who came to our attention, we observed the
absence of intrathecal synthesis of SARS-CoV-2 antibod-
ies together with a massive increase of CSF phosphoryl-
ated neurofilament heavy chain (pNfH) and serum neuro-
filament light chain (NfL) proteins, supporting the role of
neurochemical markers as easily implementable tools for the
detection of nervous system affection in COVID-19-related
diseases [81, 82].
At variance with CSF findings, we found a discrepancy
concerning MRI findings between classic GBS and COVID-
19-related GBS. Specifically, while most cases of the for-
mer group showed typically spinal root enhancement at MRI
[83], in the latter group, in analogy with Zika-associated
g\ Springer
GBS, the same finding was less frequently reported [84].
However, caution should be warranted in the interpretation
of these results, given that MRI findings might have been
underestimated, due to lack of a sufficient number of exams
in the context of pandemic-imposed restrictions in the rou-
tine clinical setting.
Regarding the distribution of GBS electrophysiological
variants, our analysis showed that COVID-19-associated
GBS manifests prevalently with AIDP and, to a lesser extent,
with AMSAN and AMAN, in line with classic GBS in West-
ern countries [66, 85]. Conversely, the observation of posi-
tive anti-GD1b antibodies in one COVID-19-related MFS
patient and negative anti-ganglioside antibodies in other
five cases appear in discordance with the high prevalence
(~90%) of anti-GQ1b antibodies among non-COVID-19
MEFS cases [86], and may suggest different immune-medi-
ated mechanisms. However, these results could not be gen-
eralized until a wider population would be tested.
In analogy to classic GBS, approximately one-fifth of
COVID-19-associated GBS subjects required mechanical
ventilation during hospitalisation [87]. In this regard, cases
with no improvement or unfavorable outcome showed, in
comparison to those with a good prognosis, an older age,
confirming similar findings both in classic GBS [58, 88] and
in COVID-19 [89], and a slightly higher frequency (with-
out reaching a statistical significance) of past or concurrent
COVID-19 pneumonia. However, given the short follow-up
time in most cases, we could not reach a definite conclu-
sion on the impact of past or concurrent COVID-19 restric-
tive syndrome due to pneumonia on the prognosis of GBS
patients. Future prospective studies are needed to clarify this
issue. Moreover, given that also preceding diarrhea (mostly
caused by Campylobacter Jejuni infection) is a strong
negative prognostic factor in classic GBS [57, 88], further
prospective studies are needed to compare the severity of
GBS related to COVID-19 to that associated with C. jejuni.
Finally, in the context of respiratory failure and ventilation
associated with COVID-19, the differential diagnosis should
always take into consideration critical illness neuropathy and
myopathy, which tend to develop later during the critical
course [90]. Despite these findings, approximately one-third
of COVID-19-related GBS patients showed no clinical and/
or radiological evidence of pneumonia, providing evidence
that GBS may also develop in the context of a paucisymp-
tomatic or even asymptomatic COVID-19. However, given
that among the GBS population only two asymptomatic
COVID-19 patients were reported to date, we may spec-
ulate that, in most cases, a certain degree of lung injury
(even minimal) or at least hematic dissemination (e.g., fever
underlying significant viral load) is necessary to trigger the
immuno-mediated process through lymphocytic recognition
of self-antigens or molecular mimicry.

Journal of Neurology (2021) 268:1133-1170
1167
@ April
Austria
Brazil
Canada
China
India
May
June @ July*
Iran P|
Italy
France
Germany
Morocco
Saudi Arabia
Spain
Sudan
Switzerland |
The Netherlands
Turkey
UK —
USA —_—
0
an
Fig.1 Temporal and spatial distribution of reported cases with
COVID-19-associated Guillain-Barré syndrome in literature from
1st January until 20th July 2020. The x-axis shows the number of
described patients. The y-axis illustrates the countries of provenience
Major strengths of our review are the inclusion of a high
number of patients, together with an in-depth analysis of
the clinical and diagnostic features of COVID-19-associated
GBS. We are aware that selection bias might have occurred,
given that most reported cases to date have been described
mostly in Europe (47 out of 73) and during COVID-19 high-
est spreading. Therefore, future extensive epidemiological
studies are necessary to ascertain the nature of the associa-
tion between COVID-19 and GBS (causal or coincidental).
Moreover, we cannot exclude the possibility that at least
some of the cases represent instances of CIDP, given the
frequent absence of a follow-up longer than 2 months. On
another issue, the low but possible evidence of an epidemio-
logical link between vaccines and GBS development [57,
58] should aware the clinicians of the possible occurrence
of GBS after COVID-19 vaccination in the long-term future.
In conclusion, based on the systematic review of 73 cases,
we showed that the clinical picture of COVID-19-associ-
ated GBS seems to resemble that of classic GBS or Zika-
associated GBS. Moreover, the chronological evolution, the
response to IVIG, and the absence of SARS-CoV-2 RNA
in CSF may suggest a prominent post-infectious immune-
mediated mechanism rather than a para-infectious one.
Although most cases were symptomatic for COVID-19,
10 I 20
an
of the cases. In each line, different colours represent the months of
April, May, June, and July (* until 20th July) 2020, in which the cases
were published. Abbreviations: UK, United Kingdom, USA, United
States of America
the preliminary report of a few patients without respira-
tory or systemic symptoms raises a significant healthcare
issue, namely the importance of SARS-CoV-2 testing in all
patients with suspected GBS during the pandemic, with the
aim to provide an eventual rapid case isolation. Neverthe-
less, only further analyses on more comprehensive cohorts
could help in clarifying better all these issues.
Acknowledgements Open Access funding provided by Projekt DEAL.
This work was in part supported by a COVID-19 grant from the state
Baden-Wiirttemberg.
Authors’ contributions Conceptualization: all authors; methodology,
formal analysis, and investigation: Samir Abu-Rumeileh, Ahmed
Abdelhak, and Matteo Foschi; writing—original draft preparation:
all authors; figure preparation: Matteo Foschi; writing—review and
editing: all authors; supervision: Markus Otto and Hayrettin Tumani.
Compliance with ethical standards
Conflicts of interest The authors declare that they have no conflict of
interest related to the content of this article.
Ethical standard For the present study, no authorization to an Eth-
ics Committee was asked, because the original reports, nor this work,
provided any personal information of the patients.
g\ Springer

1168
Journal of Neurology (2021) 268:1133-1170
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long
as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article’s Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in
the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
10.
11.
12.
13.
14.
15.
WHO (2020) Coronavirus disease 2019 (COVID-19). https://
www.who.int/emergencies/diseases/novel-coronavirus-2019.
Accessed 20 July 2002
Mao L, Jin H, Wang M et al (2020) Neurologic manifesta-
tions of hospitalized patients with coronavirus disease 2019 in
Wuhan, China. JAMA Neurol. https://doi.org/10.1001/jamaneurol
.2020.1127
Montalvan V, Lee J, Bueso T et al (2020) Neurological mani-
festations of COVID-19 and other coronavirus infections: a sys-
tematic review. Clin Neurol Neurosurg 194:105921. https://doi.
org/10.1016/j.clineuro.2020.105921
Koralnik IJ, Tyler KL (2020) COVID-19: a global threat to the
nervous system. Ann Neurol. https://doi.org/10.1002/ana.25807
Agosti E, Giorgianni A, D’Amore F et al (2020) Is Guillain-Barré
syndrome triggered by SARS-CoV-2? Case report and literature
review. Neurol Sci. https://doi.org/10.1007/s10072-020-04553-9
Alberti P, Beretta S, Piatti M et al (2020) Guillain-Barré syndrome
related to COVID-19 infection. Neurol Neuroimmunol Neuroin-
flamm 7(4):e741. https://doiorg/10.1212/NXI.000000000000074
1
Arnaud S, Budowski C, Ng Wing Tin S et al (2020) Post SARS-
CoV-2 Guillain-Barré syndrome. Clin Neurophysiol 131(7):1652-
1654. https://doi.org/10.1016/j.clinph.2020.05.003
Assini A, Benedetti L, Di Maio S et al (2020) New clinical mani-
festation of COVID-19 related Guillain-Barré syndrome highly
responsive to intravenous immunoglobulins: two Italian cases.
Neurol Sci. https://doi.org/10.1007/s10072-020-04484-5
Bigaut K, Mallaret M, Baloglu S et al (2020) Guillain-Barré syn-
drome related to SARS-CoV-2 infection. Neurol Neuroimmunol
Neuroinflamm 7(5):e785. https://doi.org/10.1212/nxi.0000000000
000785
Bracaglia M, Naldi I, Govoni A et al (2020) Acute inflammatory
demyelinating polyneuritis in association with an asymptomatic
infection by SARS-CoV-2. J Neurol. https://doi.org/10.1007/
s00415-020-10014-2
Camdessanche JP, Morel J, Pozzetto B et al (2020) COVID-19
may induce Guillain-Barré syndrome. Rev Neurol 176(6):516-
518. https://doiorg/10.1016/j.neurol.2020.04.003
Chan JL, Ebadi H, Sarna JR (2020) Guillain-Barré syndrome with
facial diplegia related to SARS-CoV-2 infection. Can J Neurol Sci.
https://doi.org/10.1017/cjn.2020.106
Chan M, Han SC, Kelly S et al (2020) A case series of Guillain-
Barré Syndrome following Covid-19 infection in New York. Neu-
rol Clin Pract. https://doi.org/10.1212/CPJ.QO00000000000880
Coen M, Jeanson G, Culebras Almeida LA et al (2020) Guillain-
Barré syndrome as a complication of SARS-CoV-2 infection.
Brain Behav Immun. https://doi.org/10.1016/j.bbi.2020.04.074
Ebrahimzadeh SA, Ghoreishi A, Rahimian N (2020) Guillain-
Barré Syndrome associated with the coronavirus disease 2019
Springer
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
(COVID-19). Neurol Clin Pract. https://doi.org/10.1212/
CPJ.0000000000000879
E] Otmani H, El] Moutawakil B, Rafai MA et al (2020) Covid-19
and Guillain-Barré syndrome: more than a coincidence! Rev Neu-
rol 176(6):518-519. https://doi.org/10.1016/j.neurol.2020.04.007
Esteban Molina A, Mata Martinez M, Sanchez Chueca P et al
(2020) Guillain-Barré Syndrome associated with SARS-CoV-2
infection. Med Intensiva. https://doi.org/10.1016/j.medin
.2020.04.015
Farzi MA, Ayromlou H, Jahanbakhsh N et al (2020) Guillain-
Barré syndrome in a patient infected with SARS-CoV-2, a case
report. J Neuroimmunol 346:577294. https://doi.org/10.1016/j.
jneuroim.2020.577294
Fernandez-Dominguez J, Ameijide-Sanluis E, Garcia-Cabo C
et al (2020) Miller-Fisher-like syndrome related to SARS-CoV-2
infection (COVID 19). J Neurol. https://doi.org/10.1007/s0041
5-020-09912-2
Finsterer J, Scorza FA, Ghosh R (2020) COVID-19 polyradiculitis
in 24 patients without SARS-CoV-2 in the cerebro-spinal fluid. J
Med Virol. https://doi.org/10.1002/jmv.26121
Frank CHM, Almeida TVR, Marques EA et al (2020) Guillain-
Barré Syndrome associated with SARS-CoV-2 infection in a pedi-
atric patient. J Trop Pediatr. https://doi.org/10.1093/tropej/fmaa0
44
Gigli GL, Bax F, Marini A et al (2020) Guillain-Barré syndrome
in the COVID-19 era: just an occasional cluster? J Neurol. https
://doi.org/10.1007/s00415-020-0991
1-3
Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S et al (2020) Miller
Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurol-
ogy. https://doi.org/10.1212/WNL.0000000000009619
Helbok R, Beer R, Léscher W et al (2020) Guillain-Barré syn-
drome in a patient with antibodies against SARS-COV-2. Eur J
Neurol. https://doi.org/10.1111/ene.14388
Hutchins KL, Jansen JH, Comer AD et al (2020) COVID-
19-associated bifacial weakness with paresthesia subtype of
Guillain-Barré syndrome. AJNR Am J Neuroradiol. https://doi.
org/10.3174/ajnr.A6654
Juliao Caamafio DS, Alonso Beato R (2020) Facial diplegia, a
possible atypical variant of Guillain-Barré Syndrome as a rare
neurological complication of SARS-CoV-2. J Clin Neurosci. https
://doi.org/10.1016/j.jocn.2020.05.016
Khalifa M, Zakaria F, Ragab Y et al (2020) Guillain-Barre syn-
drome associated with SARS-CoV-2 Detection and a COVID-
19 infection in a child. J Pediatric Infect Dis Soc. https://doi.
org/10.1093/jpids/piaa086
Kilinc D, van de Pasch S, Doets AY et al (2020) Guillain-Barré
syndrome after SARS-CoV-2 infection. Eur J Neurol. https://doi.
org/10.1111/ene.14398
Lampe A, Winschel A, Lang C et al (2020) Guillain-Barré syn-
drome and SARS-CoV-2. Neurol Res Pract 2:19. https://doi.
org/10.1186/s42466-020-00066-0
Lantos JE, Strauss SB, Lin E (2020) COVID-19-associated Miller
Fisher Syndrome: MRI findings. AJNR Am J Neuroradiol. https
://doi.org/10.3174/ajnr.A6609
Lascano AM, Epiney JB, Coen M et al (2020) SARS-CoV-2 and
Guillain-Barré syndrome: AIDP variant with favorable outcome.
Eur J Neurol. https://doi.org/10.1111/ene. 14368
Manganotti P, Pesavento V et al (2020) Miller Fisher syndrome
diagnosis and treatment in a patient with SARS-CoV-2. J Neuro-
virol. https://doi.org/10.1007/s 13365-020-00858-9
Manganotti P, Bellavita G, D’Acunto L et al (2020) Clinical neu-
rophysiology and cerebrospinal liquor analysis to detect Guillain
Barré syndrome and polyneuritis cranialis in COVID-19 patients:
a case series. J Med Virol. https://doi.org/10.1002/jmv.26289
Marta-Enguita J, Rubio-Baines I, Gast6n-Zubimendi I (2020)
Fatal Guillain-Barre syndrome after infection with SARS-CoV-2.

Journal of Neurology (2021) 268:1133-1170
1169
35.
36.
37.
38.
39.
40.
Al.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
Sindrome de Guillain-Barré fatal tras infeccion por el virus SARS-
CoV-2. Neurologia 35(4):265—267. https://doi.org/10.1016/j.
nrl.2020.04.004
Mozhdehipanah H, Paybast S, Gorji R (2020) Guillain-Barré
syndrome as a neurological complication of COVID-19 infec-
tion: a case series and review of the literature. Int Clin Neurosci
J 7(3):156-161
Naddaf E, Laughlin RS, Klein CJ et al (2020) Guillain-Barre syn-
drome in a patient with evidence of recent SARS-CoV-2 infection.
Mayo Clin Proc. https://doi.org/10.1016/j.mayocp.2020.05.029
Oguz-Akarsu E, Ozpar R, Mirzayev H et al (2020) Guillain-Barré
syndrome in a patient with minimal symptoms of COVID-19
infection. Muscle Nerve. https://doi.org/10.1002/mus.26992
Ottaviani D, Boso F, Tranquillini E et al (2020) Early Guillain-
Barré syndrome in coronavirus disease 2019 (COVID-19): a case
report from an Italian COVID-hospital. Neurol Sci 41(6):1351-
1354. https://doi.org/10.1007/s10072-020-04449-8
Padroni M, Mastrangelo V, Asioli GM et al (2020) Guillain-Barré
syndrome following COVID-19: new infection, old complication?
J Neurol. https://doi.org/10.1007/s004 15-020-09849-6
Paterson RW, Brown RL, Benjamin L et al (2020) The emerg-
ing spectrum of COVID-19 neurology: clinical, radiological
and laboratory findings. Brain. https://doi.org/10.1093/brain/
awaa240
Paybast S, Gorji R, Mavandadi S (2020) Guillain-Barré syndrome
as a neurological complication of novel COVID-19 infection: a
case report and review of the literature. Neurologist 25(4):101-
103. https://doi.org/10.1097/NRL.0000000000000291
Pfefferkorn T, Dabitz R, von Wernitz-Keibel T et al (2020) Acute
polyradiculoneuritis with locked-in syndrome in a patient with
Covid-19. J Neurol. https://doi.org/10.1007/s004 15-020-09897-y
Rana S, Lima AA, Chandra R et al (2020) Novel coronavirus
(COVID-19)-associated Guillain-Barré syndrome: case report. J
Clin Neuromuscul Dis 21(4):240—242. https://doi.org/10.1097/
CND.0000000000000309
Reyes-Bueno JA, Garcia-Trujillo L, Urbaneja P et al (2020)
Miller-Fisher syndrome after SARS-CoV-2 infection. Eur J Neu-
rol. https://doi.org/10.1111/ene.14383
Riva N, Russo T, Falzone YM et al (2020) Post-infectious Guil-
lain-Barré syndrome related to SARS-CoV-2 infection: a case
report. J Neurol. https://doi.org/10.1007/s004 15-020-09907-z
Sancho-Saldafia A, Lambea-Gil A, Liesa JLC et al (2020) Guil-
lain-Barré syndrome associated with leptomeningeal enhance-
ment following SARS-CoV-2 infection. Clin Med. https://doi.
org/10.7861/clinmed.2020-0213
Scheid] E, Canseco DD, Hadji-Naumov A et al (2020) Guillain-
Barré syndrome during SARS-CoV-2 pandemic: a case report
and review of recent literature. J Peripher Nerv Syst. https://doi.
org/10.1111/jns.12382
Sedaghat Z, Karimi N (2020) Guillain Barre syndrome associ-
ated with COVID-19 infection: a case report. J Clin Neurosci
76:233-235. https://doi.org/10.1016/j.jocn.2020.04.062
Sidig A, Abbasher K, Abbasher H et al. (2020). COVID-19 and
Guillain-Barre syndrome case report. J Neurol Neurobiol 6(3)
Su XW, Palka SV, Rao RR et al (2020) SARS-CoV-2-associated
Guillain-Barré syndrome with dysautonomia. Muscle Nerve. https
-//doi.org/10.1002/mus.26988
Tiet MY, AlShaikh N (2020) Guillain-Barré syndrome associated
with COVID-19 infection: a case from the UK. BMJ Case Rep
13(7):e236536
Toscano G, Palmerini F, Ravaglia S et al (2020) Guillain-Barré
syndrome associated with SARS-CoV-2. N Engl J Med. https://
doi.org/10.1056/nejmc2009191
Velayos Galan A, Del Saz Saucedo P, Peinado Postigo F et al
(2020) Guillain-Barré syndrome associated with SARS-
CoV-2 infection. Sindrome de Guillain-Barré asociado a
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
infeccién por SARS-CoV-2. Neurologia 35(4):268—269. https://
doi.org/10.1016/j .nrl.2020.04.007
Virani A, Rabold E, Hanson T et al (2020) Guillain-Barré
Syndrome associated with SARS-CoV-2 infection. [DCases
20:e00771. https://doi.org/10.1016/j.idcr.2020.e00771
Webb S, Wallace VC, Martin-Lopez D et al (2020) Guillain-
Barré syndrome following COVID-19: a newly emerging post-
infectious complication. BMJ Case Rep 13(6):e236182. https://
doi.org/10.1136/bcer-2020-236182
Zhao H, Shen D, Zhou H et al (2020) Guillain-Barré syndrome
associated with SARS-CoV-2 infection: causality or coincidence?
Lancet Neurol 19(5):383-384. https://doi.org/10.1016/S
1474
-4422(20)30109-5
Leonhard SE, Mandarakas MR, Gondim FAA et al (2019) Diag-
nosis and management of Guillain-Barré syndrome in ten steps.
Nat Rev Neurol 15(11):671-683. https://doi.org/10.1038/s4158
2-019-0250-9
Willison HJ, Jacobs BC, van Doorn PA (2016) Guillain-Barré
syndrome. Lancet 388(10045):717—727. https://doi.org/10.1016/
$0140-6736(16)00339-1
Kieseier BC, Mathey EK, Sommer C et al (2018) Immune-medi-
ated neuropathies. Nat Rev Dis Primers 4:31
Wakerley BR, Yuki N (2015) Polyneuritis cranialis-subtype of
Guillain-Barré syndrome? Nat Rev Neurol 11(11):664. https://
doi.org/10.1038/nrneurol.2015.115
Uncini A, Kuwabara S (2018) The electrodiagnosis of Guillain-
Barré syndrome subtypes: where do we stand? Clin Neurophysiol
129(12):2586-2593. https://doi.org/10.1016/j.clinph.2018.09.025
Costello F, Dalakas MC (2020) Cranial Neuropathies and COVID-
19: neurotropism and Autoimmunity. Neurology. https://doi.
org/10.1212/WNL.0000000000009921
Kim JE, Heo JH, Kim HO et al (2010) Neurological complications
during treatment of Middle East Respiratory Syndrome. J Clin
Neurol 13(3):227-233
Zhou Z, Kang H, Li S et al (2020) Understanding the neurotropic
characteristics of SARS-CoV-2: from neurological manifestations
of COVID-19 to potential neurotropic mechanisms. J Neurol. https
://doi.org/10.1007/s00415-020-09929-7
Grant MJ, Booth A (2009) A typology of reviews: an analysis of
14 review types and associated methodologies. Health Info Libr
J 26:91-108
Fokke C, van den Berg B, Drenthen J et al (2014) Diagnosis of
Guillain-Barre syndrome and validation of Brighton criteria.
Brain 137(Pt 1):33-43
Desforges M, Le Coupanec A, Brison E et al (2014) Neuroinva-
sive and neurotropic human respiratory coronaviruses: potential
neurovirulent agents in humans. Adv Exp Med Biol 807:75-96.
https://doi.org/10.1007/978-8 1-322-1777-0_6
Dalakas MC (2020) Guillain-Barré syndrome: the first docu-
mented COVID-19-triggered autoimmune neurologic disease:
More to come with myositis in the offing. Neurol Neuroimmunol
Neuroinflamm 7(5):e781
Wang L, Shen Y, Li M et al (2020) Clinical manifestations and
evidence of neurological involvement in 2019 novel coronavirus
SARS-CoV-2: a systematic review and meta-analysis. J Neurol.
https://doi.org/10.1007/s00415-020-09974-2
Guan WJ, Ni ZY, Hu Y et al (2020) Clinical characteristics of
coronavirus disease 2019 in China. N Engl J Med 382(18):1708-
1720. https://doi.org/10.1056/NEJMoa2002032
Jin JM, Bai P, He W et al (2020) Gender differences in patients
with COVID-19: focus on severity and mortality. Front Public
Health 8:152. https://doi.org/10.3389/fpubh.2020.00152
Dirlikov E, Major CG, Medina NA et al (2018) Clinical features
of Guillain-Barré syndrome with vs without zika virus infection,
Puerto Rico, 2016. JAMA Neurol 75(9):1089-1097. https://doi.
org/10.1001/jamaneurol.2018.1058
g\ Springer

1170
Journal of Neurology (2021) 268:1133-1170
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
ECDC (2020) https://covid19-surveillance-report.ecdc.europa.eu,
Accessed 20 July 2002
WHO (2020) https://www.who.int/emergencies/diseases/novel
-coronavirus-2019/situation-reports/, Accessed 20 July 2020
Parra B, Lizarazo J, Jiménez-Arango JA et al (2016) Guillain-
Barré Syndrome Associated with Zika Virus Infection in Colom-
bia. N Engl J Med 375(16):1513-1523
Balcioglu YH, Yesilkaya UH, Gokcay H et al (2020) May the
central nervous system be fogged by the cytokine storm in
COVID-19?: an Appraisal. J Neuroimmune Pharmacol. https://
doi.org/10.1007/s11481-020-09932-9
Costela-Ruiz VJ, Ilescas-Montes R, Puerta-Puerta JM et al (2020)
SARS-CoV-2 infection: the role of cytokines in COVID-19 dis-
ease. Cytokine Growth Factor Rev. https://doi.org/10.1016/j.cytog
fr.2020.06.001
Tumani H, Brettschneider J (2012) Biochemical markers of
autoimmune diseases of the nervous system. Curr Pharm Des
18(29):4556-4563. https://doi.org/10.2174/138161212802502143
Van der Meché FG, Van Doorn PA, Meulstee J et al (2001)
GBS-consensus group of the Dutch Neuromuscular Research
Support Centre. Diagnostic and classification criteria for the
Guillain-Barré syndrome. Eur Neurol 45(3):133-139. https://doi.
org/10.1159/000052111
Brettschneider J, Petzold A, Siissmuth S et al (2009) CSF bio-
markers in GBS—where do we stand? J Neurol 256(1):3-12
Senel M, Abu-Rumeileh S, Michel D et al (2020) Miller-Fisher
syndrome after COVID-19: neurochemical markers as an early
sign of nervous system involvement. Eur J Neurol. https://doi.
org/10.1111/ene.14473
Ameres M, Brandstetter S, Toncheva AA et al (2020) Association
of neuronal injury blood marker neurofilament light chain with
mild-to-moderate COVID-19. J Neurol. https://doi.org/10.1007/
s00415-020-10050-y
g\ Springer
83.
84.
85.
86.
87.
88.
89.
90.
Berciano J, Sedano MJ, Pelayo-Negro AL et al (2017) Proximal
nerve lesions in early Guillain-Barré syndrome: implications for
pathogenesis and disease classification. J Neurol 264(2):221-236.
https://doi.org/10.1007/s00415-016-8204-2
Watrin L, Ghawché F, Larre P et al (2016) Guillain-Barré Syn-
drome (42 cases) occurring during a zika virus outbreak in French
Polynesia. Medicine 95(14):e3257. https://doi.org/10.1097/
MD.0000000000003257
Arcila-Londono X, Lewis RA (2020) Guillain-Barré
syndrome. Semin Neurol 32(3):179-186. https://doi.
org/10.1055/s-0032-1329196
Yoshikawa K, Kuwahara M, Morikawa M et al (2018) Varied anti-
body reactivities and clinical relevance in anti-GQI1b antibody-
related diseases. Neurol Neuroimmunol] Neuroinflamm 5(6):e501
Walgaard C, Lingsma HF, Ruts L et al (2010) Prediction of res-
piratory insufficiency in Guillain-Barré syndrome. Ann Neurol
67(6):78 1-787. https://doi.org/10.1002/ana.21976
van Koningsveld R, Steyerberg EW, Hughes RA et al (2007) A
clinical prognostic scoring system for Guillain-Barré syndrome.
Lancet Neurol 6(7):589-594. https://doi.org/10.1016/S1474
-4422(07)70130-8
Liu Y, Mao B, Liang S et al (2020) Association between age and
clinical characteristics and outcomes of COVID-19. Eur Respir J
55(5):2001112. https://doi.org/10.1183/13993003.01112-2020
Zink W, Kollmar R, Schwab S (2009) Critical illness polyneu-
ropathy and myopathy in the intensive care unit. Nat Rev Neurol
5(7):372-379. https://doi.org/10.1038/nrneurol.2009.75